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Summary 
Lympho-myeloid restricted early thymic progenitors (ETPs) are postulated to be the cell of origin for 
ETP leukemias, a therapy-resistant leukemia associated with frequent co-occurrence of EZH2 and 
RUNX1 inactivating mutations, and constitutively activating signaling pathway mutations. In a mouse 
model, we demonstrate that Ezh2 and Runx1 inactivation targeted to early lymphoid progenitors 
causes a marked expansion of pre-leukemic ETPs, showing transcriptional signatures characteristic of 
ETP leukemia. Addition of a RAS-signaling pathway mutation (Flt3-ITD) results in an aggressive 
leukemia co-expressing myeloid and lymphoid genes, which can be established and propagated in 
vivo by the expanded ETPs. Both mouse and human ETP leukemias show sensitivity to BET inhibition 
in vitro and in vivo, which reverses aberrant gene expression induced by Ezh2 inactivation. 
 
Significance 
How the identity of the normal stem and progenitor cells targeted by oncogenic mutations impacts 
on cancer stem cell biology and the clinical picture of the resulting cancer remains to be established. 
Therapy-resistant ETP leukemias were first identified by their transcriptional profile, which 
resembled that of mouse ETPs. However, direct experimental evidence that ETPs could be the 
primary target cell for mutations associated with ETP leukemia and can propagate the disease in vivo 
remains lacking. We targeted relevant mutations to early lymphoid progenitors in mice, generating 
an aggressive lympho-myeloid leukemia propagated by an expanded ETP population, which showed 
transcriptional signatures characteristic of ETP leukemia. Using this model we identified BET 
inhibition as a promising therapeutic approach for PRC2-inactivated ETP leukemias. 
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Introduction 
Extensive efforts have shed light on the identity and biology of cancer stem cells (CSCs), required and 
sufficient for propagation of hematological malignancies and solid tumors (Magee et al., 2012). 
Much less is understood about the identity and properties of normal stem and progenitor cells 
targeted by oncogenic lesions, and how the nature of the targeted cell impacts on the biology and 
clinical picture of the resulting cancer. While in hematological malignancies CSCs frequently originate 
in normal hematopoietic stem cells (HSCs) with intrinsic self-renewal (Shlush et al., 2014; Woll et al., 
2014), it remains to be established to what degree progenitor cells that normally lack self-renewal 
potential can be transformed into leukemic stem cells (LSCs) (Magee et al., 2012), and propagate 
leukemias independently of HSCs. 
 
Whilst most acute leukemias show restricted expression of either myeloid (acute myeloid leukemia; 
AML) or lymphoid (acute lymphoblastic leukemia; ALL) antigens, subgroups show aberrant co-
expression of lymphoid and myeloid antigens. These are defined as the clinical entity of 
biphenotypic leukemia (Matutes et al., 2011). Acute leukemias can also undergo a lineage-switch 
from an ALL to AML phenotype (Dorantes-Acosta and Pelayo, 2012). These biphenotypic leukemias 
almost invariably share markers of one of the (B or T) lymphoid lineages with markers of the 
granulocyte-monocyte (GM) lineages, and rarely between B and T or lymphoid and megakaryocyte-
erythroid lineages (Matutes et al., 2011). A common lympho-myeloid pathway has been established 
in normal mouse and human hematopoiesis, with lymphoid-primed multipotent progenitors (LMPPs) 
(Adolfsson et al., 2005; Goardon et al., 2011). The presence of LMPP-like LSCs in AML patients 
(Goardon et al., 2011) is compatible with targeting of leukemia-initiating lesions to LMPPs. A 
combined lympho-myeloid program is sustained even in the earliest T cell progenitors (early thymic 
progenitors; ETPs), closely related to LMPPs (Luc et al., 2012). ETPs sustain residual myeloid lineage 
potential of unknown significance (Bell and Bhandoola, 2008; Schlenner and Rodewald, 2010). 
Overexpression of a myeloid transcription factor is sufficient to switch ETPs from a T cell to myeloid 
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lineage fate (Laiosa et al., 2006), and introduction of the Mll-Enl translocation or enhanced Myc 
expression into T-lymphoid progenitors may give rise to AML (Drynan et al., 2005; Riemke et al., 
2016). These findings suggest that targeting of relevant mutations to ETPs might underlie a clinically 
distinct subgroup of T cell ALL, characterised by aberrant co-expression of myeloid, stem/progenitor 
and T cell genes: so-called ETP acute lymphoblastic leukemia (ETP-ALL) (Coustan-Smith et al., 2009), 
distinct from other biphenotypic leukemias. 
 
ETP-ALL is therapy-resistant, with a transcriptional profile resembling normal ETPs (Coustan-Smith et 
al., 2009), and a mutational landscape distinct from other cases of T-ALL (Zhang et al., 2012a), with 
increased frequency of inactivating mutations of the transcription factor RUNX1 and components of 
the polycomb repressive complex-2 (PRC2) including EZH2. Hemizygous mutations (mutation 
combined with deletion of the other allele), causing complete loss of function, have been shown to 
occur at quite high frequencies for both of these genes in ETP-ALL (3 of 10 EZH2-mutant patients and 
2 of 10 RUNX1-mutant patients) (Zhang et al., 2012a). Furthermore, EZH2 and RUNX1 mutations co-
occur more frequently than expected by chance in ETP-ALL (Zhang et al., 2012a). Cases of ETP-ALL 
are also associated with a high frequency of activating mutations of cytokine receptors and 
components of RAS signaling in comparison with other T-ALL cases. Whereas FLT3 activating 
mutations, including internal tandem duplication (FLT3-ITD) mutations, are common in AML and rare 
in other subgroups of T-ALL, they are frequently seen in ETP-ALL (Zhang et al., 2012a). 
 
Although established as a clinically and molecularly distinct disease entity (Zhang et al., 2012a), the 
implication that ETP-ALLs derive from targeting of relevant mutations to ETPs remains to be 
established, as only correlative gene expression and immunophenotypic findings support this 
(Coustan-Smith et al., 2009). Also, direct evidence that ETPs, which normally lack self-renewal, can 
propagate acute leukemia upon introduction of ETP leukemia relevant genetic lesions remains to be 
demonstrated. The proposed origin in lympho-myeloid restricted progenitors of leukemias that 
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aberrantly co-express lymphoid and myeloid antigens remains an attractive hypothesis, yet to be 
experimentally validated. While some ALL mouse models have recapitulated certain aspects of ETP-
ALL (Danis et al., 2016; Goossens et al., 2015; Treanor et al., 2014; Yu et al., 2012), relevant genetic 
lesions have not been specifically targeted to early lympho-myeloid progenitors, including ETPs. 
 
Results 
Inactivation of Ezh2 and Runx1 Targeted to Early Lymphoid Progenitors Collaborate to Cause a 
Marked Expansion of ETPs 
Mutations of EZH2 and RUNX1, found in ETP leukemias, confer loss-of-function (Della Gatta et al., 
2012; Zhang et al., 2012a). Pan-hematopoietic deletion, including in HSCs, of Ezh2 and Runx1 using 
Mx1Cre resulted in a highly penetrant and fatal myelodysplastic syndrome (MDS) phenotype, with 
severe pancytopenia (Figure S1A), as reported for Ezh2 deletion combined with retroviral 
overexpression of a dominant-negative Runx1-mutant (Sashida et al., 2014). To target the early 
lymphoid/lympho-myeloid progenitor compartment (Boiers et al., 2013), we generated 
Ezh2fl/fl;Runx1fl/fl;Rag1Cre+ double knockout (DKO) mice as well as Ezh2fl/fl;Runx1+/+;Rag1Cre+ (Ezh2 
KO) and Ezh2+/+;Runx1fl/fl;Rag1Cre+ (Runx1 KO) single knockout, and Rag1Cre- wild-type (WT) controls 
(Figure 1A). This induced close to 100% recombination in Lin-CD4-CD8-CD44+CD25-Kit+Flt3+ ETPs, with 
no detectable deletion in the bone marrow (BM) Lin-Kit+Sca1+CD150+CD48- HSC compartment (Kiel et 
al., 2005) (Figure S1B). At 6 weeks of age, DKO mice developed significant leucopenia (Figure 1B; 
x0.52; p<0.001) caused by loss of CD4+ and/or CD8+ T cells and CD19+ B cells (Figure 1C). A similar 
leucopenia was present in both Ezh2 KO and Runx1 KO mice, in keeping with a block in B and T cell 
differentiation in both Runx1 and Ezh2 knockout (Ichikawa et al., 2004; Su et al., 2003; Su et al., 
2005). DKO as well as Ezh2 KO and Runx1 KO mice developed mild anemia (Figure 1B). Although loss 
of Runx1 is associated with megakaryocyte maturation defects (Ichikawa et al., 2004), no significant 
impact on platelet counts were seen upon Runx1 or Ezh2 deletion (Figure 1B), in keeping with 
absence of Rag1Cre-induced deletion during megakaryocytic differentiation (Boiers et al., 2013). 
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Thymus cellularity was markedly reduced in DKO (x0.062; p<0.001), Ezh2 KO and Runx1 KO mice 
(Figure 1D). Staging of thymocytes (Figures 1E and S1C) revealed a striking increase in absolute 
numbers of ETPs (x12.3; p<0.001; Figure 1F) and Lin-CD4-CD8-CD44+CD25+ DN2 cells (x8.3; p<0.001; 
Figure S1D); stages of thymocyte progenitors which sustain myeloid and T lineage potential (Bell and 
Bhandoola, 2008). This was not observed in Ezh2 KO or Runx1 KO mice. DN3 (Lin-CD4-CD8-CD44-
CD25+), DN4 (Lin-CD4-CD8-CD44-CD25-) and DP (Lin-CD4+CD8+) thymocyte progenitors, which lack 
myeloid potential, were unaffected or reduced in DKO mice (Figure S1D; Figure 1G). These data are 
consistent with a selective expansion of ETPs in DKO mice and a block at the DN2 to DN3 transition. 
Analysis at 6 months of age revealed an even greater expansion of ETPs (x17.9; P=0.021), despite 
reduced overall thymus cellularity (x0.098; P<0.001; Figure S1E). However, DKO mice did not show 
any evidence of MDS or leukemia development over follow-up for 1 year (Figure 1H). 
 
Disrupted Gene Expression Signatures in DKO ETPs Recapitulate Features of ETP Leukemia 
Disrupted gene expression was assessed by RNA-sequencing of WT (n=4) and DKO (n=4) ETPs (GEO: 
GSE75185), revealing 306 significantly differentially expressed genes (Table S1). Most showed 
upregulation in DKO ETPs (n=238), as expected following inactivation of a component of PRC2, which 
plays a key role in repression of gene expression (Margueron and Reinberg, 2011). A smaller number 
of genes were downregulated in DKO ETPs (n=68). WT and DKO ETPs clustered separately (Figures 
2A and S2A), and gene set enrichment analysis (GSEA) revealed upregulation of PRC2 target genes in 
DKO ETPs (Figure 2B). The expanded ETPs showed upregulation of HSC (Figures 2C and S2B) and 
myeloid (pre-GM; Figures 2D and S2C) gene expression, characteristic of ETP leukemias (Zhang et al., 
2012a). Lymphoid gene expression showed a mixed picture with many genes showing minimal 
change or upregulation (Hey1, Rag2, Il2ra), and some downregulation (Blk, Tcf7) (Figure 2E). Blk and 
Tcf7 are tumor suppressor genes in leukemia, with loss of Tcf7 implicated in ETP leukemia (Yu et al., 
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2012; Zhang et al., 2012a). Megakaryocyte/erythroid-associated gene expression is low in WT ETPs 
(Luc et al., 2012), and was not affected in DKO ETPs (pre-MegE; Figure S2D). 
 
We confirmed differential expression of a number of genes by quantitative real-time PCR (qPCR) 
(Figures S2E-G). Gene ontology analysis revealed a striking enrichment of differentially expressed 
genes in signal transduction pathways (Figure S2H). Unbiased GSEA (Table S2) revealed upregulation 
of cytokine signaling pathways; IL2/STAT5 (Figure 2F), IL6/JAK/STAT3 (Figure 2G), KRAS (also 
reciprocal downregulation of negative transcriptional targets; Figure 2H) and interferon signaling 
(Figure S2I). JAK/STAT pathway-associated transcription is upregulated in ETP leukemia relative to 
mature T cell leukemias (Zhang et al., 2012a). Characteristic of ETP leukemia (Zhang et al., 2012a), 
there was no significant enrichment of Notch1 signaling-associated gene expression (Figure S2J). 
 
Some differentially expressed genes e.g. Arpp21, Cpa3 and Mpl only showed strongly dysregulated 
expression in the presence of both mutations (Figure 2I). In contrast, downregulation of some genes 
was largely mediated by Runx1 inactivation, e.g. Ly6d and Tcf7 (Figure 2J), known direct Runx1 target 
genes (Niebuhr et al., 2013; Wu et al., 2012). Conversely, upregulation of JAK/STAT signaling 
pathway target gene Cish was primarily mediated by Ezh2 (Figure 2K). 
 
Analysis at the cell population level cannot determine whether aberrant gene expression occurs in 
cells co-expressing lymphoid and myeloid genes, characteristic of ETPs (Luc et al., 2012). Single cell 
gene expression analysis of ETPs (Figure 3A) revealed that the frequency and level of expression of 
lymphoid genes in DKO ETPs was equivalent to (Notch1, Ikzf1, Il2ra, Il7r, Nrarp) or greater than 
(Rag1, Rag2, Gata3) that seen in WT ETPs. Moreover, HSC and myeloid genes were more frequently 
expressed in DKO than WT ETPs (Figure 3A) and, crucially, increased expression of HSC (Figure 3B) 
and myeloid (Figure 3C) genes occurred in the same cells that retained expression of multiple 
lymphoid genes. HSC and myeloid genes were also co-expressed in the same cells in DKO mice 
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(Figure S3). Importantly, these aberrant combinatorial gene expression signatures, in particular 
expression of HSC-associated genes, were not present in WT ETPs. This supports that the observed 
abnormal gene expression occurs in bona fide ETPs, and is not a result of expansion of a pre-existing 
subpopulation present in thymuses of WT mice, or infiltration of the thymus by BM HSC/multipotent 
progenitor or myeloid progenitor populations. 
 
Activating Flt3 Mutation Collaborates with Inactivating Ezh2 and Runx1 Mutations to Cause Acute 
Leukemia Propagated by ETPs 
ETP leukemia has a high incidence of signaling pathway mutations such as FLT3-ITDs in comparison 
with more mature subtypes of T-ALL (Zhang et al., 2012a). Expanded ETPs in DKO mice, showing 
aberrant signaling pathway gene expression programmes, might therefore be susceptible to 
transformation by an additional, signaling pathway activating mutation. 
Ezh2fl/fl;Runx1fl/fl;Rag1Cre+;Flt3ITD/+ (DKOITD) mice showed a similar expansion of ETPs as in DKO mice 
(x17.3; p<0.001) (Figure 4A), whereas in Rag1Cre-;Flt3ITD/+ (ITD) mice ETPs were non-significantly 
reduced (x0.051; p>0.05) (Mead et al., 2013). DKOITD mice developed a highly penetrant and 
aggressive acute leukemia associated with leucocytosis, anemia, thrombocytopenia and 
splenomegaly (Figures 4B-D and S4A-B). 
 
Since latency of leukemia development was relatively short (median 65 days) and penetrance very 
high in DKOITD mice (Figure 4B), we reasoned that the combination of DKO with Flt3-ITD was likely 
to be sufficient to cause leukemia without the requirement for additional mutations. We performed 
whole exome sequencing on BM cells from eight DKOITD leukemias and two WT control mice. In 
order to identify somatic variants, we also performed sequencing on eight WT mice from another 
(unrelated) C57BL/6 mouse colony (Figure S4C). Identifying mutated genes with human orthologs 
and comparing those with the list of cancer-implicated genes in the Cancer Gene Census 
(http://cancer.sanger.ac.uk/census), we did not identify any somatically acquired leukemia-
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associated mutations, or copy number alterations in any cancer-implicated genes (Table S3), 
supporting that the combination of Ezh2 and Runx1 inactivation with Flt3-ITD is sufficient for 
generating ETP leukemia. 
 
Circulating leukemic cells expressed the myeloid marker Mac1 but not lymphoid surface markers 
(Figure 4E). BM cellularity was unchanged, but Kit+Mac1low myeloid precursor cells were increased 
(x4.02; p<0.001; Figure S4D). DKOITD leukemias displayed a number of lymphoid phenotypic 
features. Surface expression of CD3 was lacking on Mac1+ leukemia cells in DKOITD BM (Figure S4E), 
but immunohistochemistry revealed intracellular CD3 and TdT expression in leukemic cells (Figure 
4F). Cytoplasmic but not surface CD3 expression is characteristic of immature T cell progenitors and 
leukemias with immature T cell phenotype (Van Dongen et al., 1988). RNA-sequencing of Mac1+ BM 
cells from leukemic DKOITD mice (GEO: GSE75187) revealed a relative downregulation of myeloid 
programs (Figure 4G) and upregulation of early T cell associated gene expression (Figure 4H). 
Upregulated lymphoid genes included Ccr7, CD7, Il7r, Id3, Il2ra and CD48 (Figure 4I). 
Stem/progenitor associated genes including Flt3, CD34 and Ly6a were also upregulated (Figure 4J). 
Leukemia oncogenes were markedly overexpressed in Mac1+ leukemic cells (Tspan3, Rasgrp1, Pvt1, 
Ccnd2, Hmgn1; Figure S4F). To determine whether gene expression in these cells recapitulated 
human ETP leukemia, we used published datasets comparing ETP-ALL with non-ETP T-ALL (Zhang et 
al., 2012a). As an equivalent comparison for our model, we used published RNA-seq data from a 
Notch1 mutant-driven mouse T-ALL (Ntziachristos et al., 2014). GSEA showed that genes 
upregulated in human ETP-ALL were also upregulated in DKOITD Mac1+ BM cells relative to mouse 
Notch1 T-ALL (Figure 4K). Downregulated genes also strongly overlapped between these two 
comparisons (Figure 4K), confirming the relevance of this ETP leukemia mouse model for human ETP 
ALL. 
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DKOITD ETPs were more proliferative than WT or DKO ETPs in vitro (Figure 5A). While WT ETPs are 
incapable of long-term reconstitution upon transplantation (Luc et al., 2012), unenriched 
thymocytes transplanted from DKOITD mice resulted in acute leukemia (n=4; data not shown). We 
next transplanted purified CD45.2 ETPs, DN2 cells and CD4/CD8 double and/or single positive 
thymocytes (Figure 5B). Only DKOITD ETPs were capable of engrafting and propagating the leukemia 
(Figure 5C), when isolated from leukemic (n=1) and pre-leukemic (n=3) mice. Recipients showed the 
typical leukemic features of primary DKOITD mice with anemia, thrombocytopenia and leucocytosis 
(Figure 5D), blast and monocyte precursor morphology (Figure S5A) and intracellular CD3 (Figure 5E). 
Consistent with their ETP rather than HSC origin, transplanted CD45.2 DKOITD ETPs did not 
contribute to the HSC compartment (Figure 5F), although there was a marked suppression of WT 
CD45.1 competitor HSCs (x0.035; p=0.0065). In contrast, Lin-Sca1+Kit+Flt3high LMPPs, a thymus-
seeding progenitor population closely resembling ETPs (Luc et al., 2012), were expanded and almost 
exclusively DKOITD ETP-derived (x164; p=0.20). Concurrently, thymic ETPs were exclusively derived 
from transplanted ETPs, with progressively reduced contribution to downstream thymocytes (Figure 
S5B). 
 
RNA-sequencing of ETPs from DKOITD mice (GEO: GSE75185) revealed 481 differentially expressed 
genes in comparison with WT ETPs and 31 in comparison with DKO ETPs (Table S4; Figures 6A-B). In 
keeping with the small number of differentially expressed genes, unsupervised hierarchical 
clustering did not clearly separate DKOITD from DKO ETPs (Figure S6A). Unsupervised GSEA showed 
enrichment of signaling pathway associated gene expression (Table S5) in comparison with WT ETPs. 
Furthermore, G2M checkpoint genes, thought to limit proliferation of pre-malignant cells (Lobrich 
and Jeggo, 2007), were markedly downregulated in DKOITD ETPs (Figure 6C and Table S5). QPCR 
showed further upregulation of signaling (Figure 6D), myeloid (Figure S6B) and HSC (Figure S6C) gene 
expression in DKOITD cells in comparison to WT and DKO ETPs. PCA of single cell gene expression 
data showed that the vast majority of DKOITD ETPs clustered together with DKO ETPs but separately 
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from WT ETPs and LMPPs of all genotypes (Figure S6D), supporting that leukemia-propagating 
DKOITD ETPs represent thymus-resident progenitors, closely related to DKO ETPs, rather than a 
population of leukemic cells from DKOITD BM having infiltrated the thymus. WT and DKO HSCs also 
clustered together, in keeping with the lack of deletion of Ezh2 and Runx1 in HSCs (DKOITD HSCs 
were not analysed owing to their rarity (Figure 5F)). Further, DKO and DKOITD ETPs clustered 
separately from WT ETPs, in contrast to LMPPs which overlapped in WT, DKO and DKOITD mice 
(Figure S6D). Importantly, disease propagating DKOITD ETPs showed marked enrichment for 
signatures characteristic of human ETP-ALL (Figures 6E and S6E). 
 
To further substantiate the importance of RAS pathway signaling, we performed phospho-flow 
analysis on Lin-Kit+ BM progenitor cells (ETPs were too rare to be analysed using this method). 
Phosphorylation of the S6 ribosomal protein, upregulated in response to RAS pathway signaling 
(Roux et al., 2007), was increased in DKOITD cells (Figure 6F). In contrast, Flt3-ITD alone only had a 
minor effect on the phospho-S6 level. This increased signaling could be reversed using the MEK 
inhibitor PD-901 (Figure 6G), demonstrating specific enhancement of signaling via the RAS pathway 
in DKOITD cells. Therefore, deletion of Ezh2 and Runx1 act synergistically with a constitutive 
signaling mutation such as Flt3-ITD to increase RAS pathway signaling in an in vivo model of ETP ALL. 
 
BET Inhibition Reverses Gene Expression Changes Associated with Loss of PRC2 Function and Inhibits 
Proliferation of ETP-Propagated Leukemia Cells 
A study of peripheral nerve sheath tumors showed that aberrant upregulation of RAS pathway 
signaling is enhanced by inactivation of PRC2, due to PRC2 inactivation-associated loss of the 
H3K27me3 repressive histone mark leading to a consequential increase in H3K27ac, and activation 
of gene transcription via recruitment of the bromodomain and extra terminal (BET) proteins (De 
Raedt et al., 2014). Such tumors are sensitive to BET protein inhibition. We compared ChIP-seq 
analysis for H3K27me3 and H3K27ac on BM cells from DKOITD and WT mice (GEO: GSE100693) with 
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RNA-seq data from Mac1+ BM cells (Figures 7A, S7A and Table S6). We first established gene loci that 
showed significantly increased or decreased presence of H3K27me3 or H3K27ac at the transcription 
start site in DKOITD relative to WT cells (Table S6). There was an overall loss of H3K27me3 at 
transcription start sites genome-wide, and genes showing a significant loss of H3K27me3 at the 
transcription start site showed a reciprocal gain in H3K27ac (Figures 7B and S7B). We compared 
genes showing both loss of H3K27me3 and gain of H3K27ac in DKOITD compared to WT BM cells 
with differentially expressed genes by RNA-seq in DKOITD relative to WT BM (Figures 7C-D and S7C). 
The Flt3 gene locus showed clear loss of H3K27me3 and gain of H3K27ac (Figure 7D), corresponding 
to a marked upregulation in Flt3 gene expression (Figure 4J). This illustrates how loss of H3K27me3 
associated gene repression can lead to over-expression of oncogenic mutations, promoting 
leukemogenesis. Loss of H3K27me3 and gain of H3K27ac was associated with marked upregulation 
of gene expression across all genes (Figure 7E). Genes showing both reduced H3K27me3 and 
increased H3K27ac overlapped significantly with genes showing upregulated expression (p=1.16 x10-
22). These results confirm that EZH2 inactivation-associated epigenetic changes directly lead to 
aberrant upregulation of relevant gene transcription in this ETP leukemia mouse model. 
 
We next performed RNA-seq and ChIP-seq experiments in the human LOUCY cell line (experimental 
outline Figure S7D; GSE100694). Although originating from before the disease entity was formally 
recognised, LOUCY cells show an ETP-ALL gene expression signature and were likely derived from an 
ETP-ALL patient (Van Vlierberghe et al., 2011). In agreement, we confirmed upregulation of ETP-ALL 
associated gene expression in LOUCY cells in comparison with the mature T-ALL cell line JURKAT 
(Figure S7E). Notably, LOUCY cells do not express EZH2 and show minimal H3K27me3 genome-wide 
(Figure S7F). RNA-seq analysis demonstrated that LOUCY cells clustered separately from JURKAT cells 
and that treatment with the BET inhibitors JQ1 and I-BET151 led to similar changes in gene 
expression, with treated LOUCY cells reproducibly clustering separately from untreated cells (Figure 
7F). BET inhibition in LOUCY cells caused marked downregulation of genes showing H3K27ac at the 
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transcription start site (Figure 7G). Genes downregulated following BET inhibition included MYC, 
KRAS and JAK-STAT pathways (Figure 7H and Table S7). Genes highly upregulated in DKOITD (ETPs 
and/or Mac1+ BM cells) were also enriched among genes downregulated by BET inhibition in LOUCY 
cells (Figure 7I). One of these, which was not expressed at all in JURKAT, was the HSC-related gene 
MPL (Log2FC=-1.91, FDR=4.03x10-9). This was one of the most significantly upregulated genes in 
both DKO and DKOITD relative to WT ETPs (Figure 2A and Tables S1 and S4), and was therefore 
selected for further study in the mouse lympho-myeloid progenitor cell line EML. Using ChIP-qPCR 
we found that drug-mediated Ezh2 inhibition resulted in loss of H3K27me3 and a corresponding 
increase in H3K27ac at the Mpl locus (Figure 7J). This was associated with increased expression, an 
effect fully reversed by JQ1 treatment (Figure 7K). 
 
Together, these results establish that upregulated oncogenic gene expression resulting from 
epigenetic changes induced by loss of EZH2, in both mouse and human ETP leukemias, can be 
reversed by BET inhibition. 
 
We next assessed whether BET inhibitors were effective against DKOITD leukemia. DKOITD 
leukemia-propagating ETPs were highly sensitive to JQ1 in vitro (Figures 8A and S8A). Observed IC50 
values were comparable to those for human cell lines reported to be sensitive to JQ1 (NB4, HL-60 
and THP-1), in comparison to known resistant cell lines (JURKAT and K562; Figure S8B) (Zuber et al., 
2011). The inhibitory effect of both JQ1 (Figure 8B) and I-BET151 (Figure S8C) was significantly 
greater on Lin-Kit+ BM progenitors from leukemic DKOITD ETP transplant recipient mice than from 
WT BM. Mice transplanted with BM cells from DKOITD mice were next treated with JQ1 in vivo. JQ1 
treatment significantly reduced tumor burden, as measured by peripheral blood leukocyte counts, 
and BM and spleen cellularity (Figure 8C), findings replicated with I-BET151 (Figure S8D). 
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LOUCY cells were also highly sensitive to both JQ1 (Figure 8D) and I-BET151 (Figure S8E) treatment. 
We next tested two ETP-ALL samples derived from separate patients (Maude et al., 2015), both 
carrying inactivating mutations in PRC2 components, one in EZH2 as well as RUNX1 (ETP-ALL 12), and 
the other in EED (ETP-ALL 13) (see STAR Methods). These showed higher sensitivity to both JQ1 
(Figure 8E) and I-BET151 (Figure S8F) inhibition in vitro compared to the three tested non-ETP T-ALL 
samples. We transplanted these PRC2-mutant ETP-ALLs into immunodeficient NSG mice, and started 
treatment with either DMSO or JQ1 in vivo upon confirmation of engraftment. JQ1 treatment 
markedly inhibited progression of EZH2 and RUNX1-mutant ETP leukemia (Figure 8F), with 
significantly reduced leukocyte counts and human cell chimerism in BM and spleen. This was 
accompanied by a relative preservation of normal hematopoiesis in BM and spleen, supporting that 
JQ1 was selectively targeting human ETP leukemia cells whilst preserving normal mouse 
hematopoietic cells. We obtained similar data from the EED-mutant ETP leukemia (Figure 8G), where 
JQ1 treatment completely halted leukemia progression and strongly reduced human cell 
composition of the blood leukocytes, BM and spleen. 
 
Collectively, these data support that ETP-propagated PRC2-deficient leukemia is sensitive to BET 
inhibition, providing experimental support for an approach to treat ETP leukemia associated with 
loss of PRC2 function. 
 
Discussion 
While there is compelling evidence that HSCs, which already possess intrinsic self-renewal potential, 
might represent the only LSCs in chronic myeloid malignancies (Woll et al., 2014), there is less 
definitive evidence for the hypothesis that progenitors which normally lack extensive self-renewal 
potential might be the primary target of recurrent leukemogenic mutations, becoming LSCs, in acute 
leukemias (Magee et al., 2012). 
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The hypothesis for an ETP origin and LSC identity in ETP-ALL is primarily based on a similar gene 
expression signature of leukemic cells from ETP-ALL cases, to that of normal mouse ETPs (Coustan-
Smith et al., 2009). However, whether thymus-residing ETPs with sustained lympho-myeloid 
potential (Bell and Bhandoola, 2008; Luc et al., 2012) are susceptible to transformation by ETP 
leukemia associated mutations has yet to be established. We herein demonstrate that Rag1Cre-
mediated targeting of Ezh2 and Runx1 inactivation to early lympho-myeloid progenitors, including 
ETPs (but excluding HSCs and multipotent progenitors), causes a marked expansion of stringently 
defined ETPs (Luc et al., 2012), with a loss of later stages of thymocyte development. Importantly, 
inactivation of Ezh2 or Runx1 individually had no impact on ETP numbers, helping to explain why the 
presence of these two mutations is positively correlated in human ETP leukemias (Zhang et al., 
2012a). Selectivity of targeting of these mutations to early lympho-myeloid progenitors was 
confirmed by lack of deletion in HSCs, and by the distinct impact of HSC-targeted deletion of Ezh2 
and Runx1 using Mx1-Cre, which instead caused a MDS phenotype. In contrast, expanded “pre-
leukemic” ETPs in Rag1Cre-induced DKO mice showed gene expression changes reminiscent of ETP 
leukemias, with upregulation of myeloid, HSC and cytokine signaling-associated gene expression. 
Single-cell gene expression analysis revealed co-expression of lymphoid and myeloid genes, 
characteristic of ETPs, with aberrant expression of HSC associated genes, helping to explain how 
inactivation of Ezh2 and Runx1 contributes towards establishment of pre-LSC potential in bona fide 
ETPs. 
 
We reasoned that pre-leukemic DKO ETPs might be susceptible to additional mutations causing 
constitutive activation of signaling pathways, as frequently observed in ETP leukemia (Zhang et al., 
2012a). While rare in other T cell leukemias, FLT3 activating mutations occur quite frequently in ETP 
leukemias (around 14% of cases) (Zhang et al., 2012a). DKOITD mice developed a highly penetrant, 
aggressive acute leukemia with co-expression of myeloid and T-lymphoid lineage programs. Exome 
sequencing analysis, and the high penetrance and short latency of disease, support that the 
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combination of Ezh2 and Runx1 inactivation with Flt3-ITD is sufficient to induce this leukemia 
phenotype. Purified DKOITD ETPs fulfilled the LSC definition, by establishing and propagating the 
same type of leukemia upon transplantation, whereas other thymic progenitors had no LSC 
potential. DKOITD ETPs downregulated multiple G2M checkpoint genes that might otherwise have 
limited the proliferation of pre-malignant DKO ETPs (Lobrich and Jeggo, 2007). DKOITD ETPs also 
showed aberrant gene expression programmes closely paralleling those seen in human ETP 
leukemia. These findings provide evidence supporting that ETPs carrying a combination of ETP 
leukemia-associated mutations can act as LSCs and establish and propagate a lympho-myeloid 
leukemia in vivo. 
 
Phospho-flow analysis established that DKOITD Lin-Kit+ stem/progenitor cells show greatly enhanced 
RAS pathway signaling compared to those from DKO and ITD mice. Combined with our gene 
expression data, these findings suggest that Ezh2 and Runx1 deletion establishes an altered 
transcriptional environment which increases RAS pathway-associated transcription, but only 
increases RAS signaling to a small extent. The additional hit of Flt3-ITD further increases RAS 
pathway signaling and proliferation, dependent on the altered transcription established by Ezh2 and 
Runx1. This may help to explain why as many as 67% of ETP-ALLs carry mutations in signaling 
pathway components such as FLT3-ITD, and that these are often combined with mutations in genes 
involved in epigenetic and transcriptional regulation, such as EZH2 and RUNX1 (Zhang et al., 2012a). 
 
Previous mouse models, although displaying some features compatible with ETP-ALL, have not 
targeted relevant mutations specifically to ETPs rather than HSCs, nor observed the expected 
expansion of carefully defined ETPs, nor performed the critical experiments to establish the LSC 
potential of ETPs (Danis et al., 2016; Goossens et al., 2015; Treanor et al., 2014; Yu et al., 2012). In 
the present studies, when transplanted into recipient mice, ETP-LSCs propagated an aggressive 
lympho-myeloid leukemia with a severe suppression of normal HSCs and expansion of BM-residing 
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LMPPs and thymic ETPs. These data provide definitive evidence for the leukemia-propagating 
potential of ETPs targeted with ETP-ALL relevant mutations, and are also compatible with initiation 
of ETP leukemia in the ETP population itself. Initiation of ETP leukemia may also occur in common 
lymphoid progenitors or the closely-related BM LMPPs, representing thymus-seeding progenitors 
which upon thymus entry become ETPs (Bell and Bhandoola, 2008; Luc et al., 2012). However, single 
cell gene expression analysis indicated that the key impact of Ezh2 and Runx1 inactivation in our 
mouse model was on thymus-residing ETPs and not LMPPs, as DKO LMPPs clustered close to WT 
LMPPs, in contrast to DKO ETPs and WT ETPs which formed highly distinct clusters. While the 
physiological relevance of the sustained myeloid lineage potential of ETPs and LMPPs remains 
unclear, our data support the possibility that it underlies the lympho-myeloid phenotype of ETP 
leukemias. This is also of possible broader relevance for the cell of origin of the distinct clinical entity 
of biphenotypic leukemias, which also show co-expression of lymphoid and myeloid antigens 
(Matutes et al., 2011), but for which the cell of origin remains to be established. The myeloid 
phenotype might also be promoted by mutations such as FLT3-ITD, which enhance myeloid 
differentiation bias of MPPs (Mead et al., 2013). 
 
Our findings also support BET inhibition as a promising therapeutic approach for ETP leukemia. In 
solid tumors, recent evidence indicates that loss of PRC2 function is associated with aberrant 
upregulation of RAS pathway signaling, which collaborates with other mutations causing constitutive 
signaling to promote tumor growth. This renders such tumors sensitive to BET inhibition (De Raedt 
et al., 2014). Here, we obtained a number of lines of evidence that Ezh2 mutation-associated loss of 
H3K27me3 results in the gain of H3K27ac that underlies the aberrant transcriptional programmes in 
mouse and human PRC2-inactivated ETP leukemia. This aberrant transcription could be reversed 
with BET inhibitors. Notably, the Flt3 gene locus showed marked loss of H3K27me3 and gain of 
H3K27ac in DKOITD BM, which correlated with strongly upregulated Flt3 expression. This helps to 
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explain the synergy between DKO and Flt3-ITD, as loss of Ezh2 function in DKO mice drives increased 
expression of the oncogenic signaling by Flt3-ITD in this model. 
 
We further demonstrated that primary mouse DKOITD ETP leukemias, a human ETP leukemia cell 
line associated with EZH2 loss of function, as well as patient-derived ETP leukemia xenografts 
carrying PRC2 loss-of-function mutations were all highly sensitive to BET inhibition both in vitro and 
in vivo. Crucially, in vivo treatment selectively targeted the ETP leukemia cells whilst leaving normal 
hematopoietic cells relatively intact. Intriguingly, in an MLL-AF9 driven AML model, it has recently 
been shown that suppression of the PRC2 complex promotes BET inhibitor resistance in AML 
(Rathert et al., 2015), suggesting that the cellular context in which PRC2 inactivation occurs might be 
crucial. For example, whilst EZH2 inactivating mutations occur in ETP leukemia, MLL associated 
leukemias frequently overexpress EZH2 and are susceptible to EZH2 inhibition (Neff et al., 2012). 
This clearly illustrates that the impact of EZH2 inactivation is highly dependent on the targeted cell 
type and the presence of collaborating mutations, and consequently that findings in one model 
system cannot be extrapolated to other contexts without careful validation. 
 
In summary, the current work has revealed a pronounced impact of combined inactivating 
mutations of Ezh2 and Runx1 on early thymocyte development, leading to a marked expansion of 
ETPs and subsequent differentiation block. This, together with a Flt3-ITD signaling mutation, results 
in establishment of ETP-LSCs which can propagate an aggressive lympho-myeloid leukemia. These 
findings provide new evidence directly linking the phenotype of a malignant disease with the 
progenitor cell of origin, in this case the development of a lympho-myeloid leukemia due to initiating 
mutations occurring within a lympho-myeloid progenitor population. In addition, this mouse model 
also provides support for exploring BET inhibition as a therapeutic strategy in PRC2-inactivated 
human ETP leukemias, which frequently show resistance to conventional therapeutic approaches. 
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Figure Legends 
Figure 1: Inactivation of Ezh2 and Runx1 Targeted to Early Lymphoid Progenitors Collaborate to 
Cause a Marked Expansion of ETPs 
(A) Experimental design. DKO = double knockout. (B) Hematological parameters, 6-8 week old mice 
(WT n=25, Ezh2 KO n=13, Runx1 KO n=6, DKO n=12). FC; Fold Change. (C) FACS analysis of absolute 
numbers of CD19+ (B cell), CD4+ and/or CD8+ (T cells) and Mac1+ (myeloid cells) cells per ml blood 
(WT n=9, Ezh2 KO n=4, Runx1 KO n=4, DKO n=5). (D) Total thymus cellularity (WT n=26, Ezh2 KO n=9, 
Runx1 KO n=10, DKO n=18). (E) Representative FACS plots. Figures represent mean percentage of 
total thymocytes falling into each gate across all experiments. (F) FACS analysis of absolute numbers 
of Lin-CD4-CD8-CD44+CD25-Kit+Flt3+ ETPs per thymus (WT n=26, Ezh2 KO n=9, Runx1 KO n=10, DKO 
n=18). (G) Line chart illustrating relative proportion of indicated thymocyte progenitor populations 
relative to WT mice. (H) Leukemia-free survival curves for WT, Ezh2 KO, Runx1 KO and DKO mice. X-
axis represents age of the mice. Significance tested by log-rank test. p values by ANOVA (B-F), 
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*p<0.05, **p<0.01 and ***p<0.001. n.s.; not significant (p>0.05). Bars and horizontal lines show 
mean ± SEM. See also Figure S1. 
 
Figure 2: Disrupted Gene Expression Signatures in DKO ETPs Recapitulate Features of ETP Leukemia 
(A) Hierarchical clustering and heatmap showing expression levels, scaled per gene, of the 50 most 
significantly differentially expressed genes between WT and DKO ETPs (WT n=4, DKO n=4). Each 
replicate represents 100 purified ETPs from individual mice at 6-8 weeks of age. (B) GSEA comparing 
WT and DKO ETPs for PRC2 target genes. (C-E) Expression relative to WT of HSC (C), myeloid (D) and 
lymphoid-associated genes (E) in DKO ETPs by RNA-sequencing. (F-H) GSEA plots comparing WT and 
DKO ETPs for Il2-Stat5 signaling genes (F), Il6-Jak-Stat3 signaling genes (G) and Kras signaling genes 
(H) (upregulated genes top panel and downregulated genes bottom panel). (I-K) Relative expression 
of indicated genes in 100 ETPs from Ezh2 KO, Runx1 KO and DKO mice, relative to gene expression in 
WT ETPs by qPCR (WT n=8, Ezh2 KO n=6, Runx1 KO n=5, DKO n=7). Box plots show median, lower 
and upper quartiles. Replicates shown as dots when outside 1.5 times the inter-quartile range. See 
also Figure S2 and Tables S1 and S2. 
 
Figure 3: HSC and Myeloid Genes are Co-Expressed with Lymphoid Genes within Single DKO ETPs. 
(A) Heatmap showing co-expression of indicated genes within single WT (n=129) and DKO (n=91) 
ETPs, by single-cell qPCR. Expression levels are scaled per gene. Single ETPs were collected from 12 
WT and 9 DKO mice. FDR q values are by Kolmogorov-Smirnov test based on expression levels, 
*p<0.05, **p<0.01 and ***p<0.001. (B-C) Scatter plots showing level of co-expression of lymphoid 
with HSC (B) and myeloid genes (C) within single WT (n=129) and DKO (n=91) ETPs. Each dot 
represents a single cell, for which are plotted the number of genes showing detectable expression 
from the panel of HSC-, myeloid- and lymphoid-associated genes shown in (A). See also Figure S3. 
 
27 
 
Figure 4: Activating Flt3 Mutation Collaborates with Inactivating Ezh2 and Runx1 Mutations Targeted 
to Early Lymphoid Progenitors to Cause Acute Leukemia 
(A) Total thymus cellularity and FACS analysis of absolute numbers of ETPs per thymus in 6-8 week 
old mice (WT n=26, DKO n=18, ITD n=6, DKOITD n=16). Horizontal lines show mean ± SEM. (B) 
Leukemia-free survival curves for WT, DKO, ITD and DKOITD mice. X-axis represents age of the mice. 
Significance tested by log-rank test. (C) Hematological parameters from moribund DKOITD (n=12) 
and ITD littermate control (n=4) mice. Horizontal lines show mean ± SEM. (D) Representative images 
of blood smears and BM cytospins from leukemic DKOITD mice. Scale bars represent 20 μm. (E) FACS 
analysis of absolute numbers of CD19+ (B cells), CD4+ and/or CD8+ (T cells) and Mac1+ (myeloid cells) 
per ml blood (WT n=9, DKO n=5, ITD n=4, DKOITD n=4). Bars show mean ± SEM. (F) Representative 
images of histological sections of BM stained for hematoxylin and eosin (H&E), CD3 or TdT. Scale bar 
represents 100 μm and pertains to all panels. (G-H) GSEA plots comparing WT and leukemic DKOITD 
Mac1+ BM cells for myeloid (G) and early T cell progenitor-associated expression signatures (H). (I-J) 
Expression in leukemic DKOITD Mac1+ BM cells relative to WT of lymphoid-associated (I) and 
stem/progenitor-associated genes (J) (WT n=3, DKOITD n=4). (K) GSEA plots comparing Notch1 
mouse T-ALL and leukemic DKOITD Mac1+ BM cells for genes upregulated (top panel) or 
downregulated (bottom panel) in human ETP-ALL relative to non-ETP T-ALL. p values by ANOVA (A), 
log-rank test (B) or T-test (C), *p<0.05, **p<0.01 and ***p<0.001. n.s.; not significant (p>0.05). See 
also Figure S4 and Table S3. 
 
Figure 5: Leukemia Induced by Activating Flt3 Mutation Combined with Inactivating Ezh2 and Runx1 
Mutations can be Propagated by ETPs 
(A) In vitro granulocyte-monocyte assay of myeloid proliferative potential of ETPs from WT (n=5), 
DKO (n=4) and DKOITD (n=3) mice. 60 wells per plate were seeded with single ETPs and proliferation 
was measured following 8 days of culture. p values by T-test comparing number of wells per plate 
showing high proliferation (>50 cells). (B) Experimental design showing thymocyte population 
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sorting strategy from DKOITD (CD45.2) mice for transplantation into CD45.1 mice. (C) FACS analysis 
of level of CD45.2 chimerism of total white blood cells, myeloid (Mac1+), B (CD19+) and T (CD4+ 
and/or CD8+) cells in peripheral blood of CD45.1 recipient mice post-transplantation of FACS-purified 
CD45.2 DKOITD thymocyte populations with CD45.1 support BM cells (DP/SP n=7, DN2 n=5, ETP 
n=13). (D) Hematological parameters from mice transplanted with FACS-purified DKOITD ETPs: 16 
weeks post-transplantation for recipient mice showing no CD45.2 engraftment (n=3), and upon 
development of leukemia for recipient mice showing CD45.2 engraftment (n=4). (E) Representative 
images of histological sections of BM from transplant recipient mice stained for hematoxylin and 
eosin (H&E) or CD3. Scale bar represents 100 μm and pertains to all panels. (F) Representative FACS 
plots showing relative contribution of CD45.1 and CD45.2 cells to HSCs (Lin-Sca1+Kit+CD48-CD150+) 
and LMPPs (Lin-Sca1+Kit+Flt3high) in recipient mice transplanted with DKOITD ETPs. Figures represent 
mean percentage of total BM mononuclear cells falling into each gate across all replicates (non-
engrafted recipient mice n=3, leukemic recipient mice n=4). p values by T-test, *p<0.05, **p<0.01 
and ***p<0.001. n.s.; not significant (p>0.05). Bars and horizontal lines show mean ± SEM. See also 
Figure S5. 
 
Figure 6: Activating Flt3 Mutation Augments Upregulation of Signaling Pathway-Associated 
Transcription and Suppresses G2M Checkpoint Genes in DKO ETPs 
(A) Significantly differentially expressed genes between WT, DKO and DKOITD ETPs by RNA-
sequencing (top), and overlap of genes within each pairwise comparison (bottom) (WT n=4, DKO 
n=4, DKOITD n=4). (B) Hierarchical clustering and heatmap showing expression levels, scaled per 
gene, of all significantly differentially expressed genes between WT, DKO and DKOITD ETPs (WT n=4, 
DKO n=4, DKOITD n=4). Each replicate represents 100 purified ETPs from individual mice at 6-8 
weeks of age. (C) GSEA plot comparing DKO and DKOITD ETPs for G2M checkpoint-associated gene 
expression. (D) Expression relative to WT of signaling pathway-associated genes in DKO and DKOITD 
ETPs by qPCR (WT n=8, DKO n=7, DKOITD n=6). Box plots show median, lower and upper quartiles. 
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Replicates shown as dots when outside 1.5 times the inter-quartile range. (E) GSEA comparing WT 
DP thymocytes and DKOITD ETPs for genes upregulated in human ETP-ALL relative to non-ETP T-ALL. 
(F) FACS analysis of phospho-S6 level in WT, DKO, ITD and DKOITD Lin-Kit+ BM cells. Representative 
histograms (left), median phospho-S6 fluorescence intensities normalised to WT from 3 experiments 
(right). Bars show mean ± SEM. (G) FACS analysis of phospho-S6 in ITD and DKOITD Lin-Kit+ BM cells 
treated for 2 hr with DMSO or 2.5 μM PD-901 (MEK inhibitor). Representative histograms (left), 
median phospho-S6 fluorescence intensities normalised to WT from 3 experiments (right). Bars show 
mean ± SEM. p values by ANOVA, *p<0.05, **p<0.01 and ***p<0.001. n.s.; not significant (p>0.05). 
See also Figure S6 and Tables S4 and S5. 
 
Figure 7: BET Inhibition Reverses Gene Expression Changes Associated with Loss of PRC2 Function 
(A) Experimental design for ChIP-seq and RNA-seq experiments in WT and DKOITD BM cells. WT 
ChIP-seq n=3 (5 million Kit-enriched cells/sample), DKOITD ChIP-seq n=5 (5 million unsorted 
cells/sample), WT RNA-seq n=3 (100 Mac1+ cells/sample), DKOITD RNA-seq n=4 (100 Mac1+ 
cells/sample). (B) Normalised read density within 2 kb of the transcription start site for H3K27me3 at 
all genes (top) and H3K27ac at genes showing significantly decreased H3K27me3 in DKOITD relative 
to WT BM cells (n=520) (bottom). (C) Venn diagram showing overlap of genes displaying increased 
H3K27ac (H3K27ac Up), decreased H3K27me3 (H3K27me3 Down), and up- or downregulation of 
gene expression in DKOITD relative to WT BM. (D) Genome browser tracks showing H3K27me3 and 
H3K27ac at the Flt3 locus in WT and DKOITD BM cells. Fold change refers to gene expression in 
DKOITD relative to WT Mac1+ BM cells. (E) GSEA comparing WT and DKOITD Mac1+ BM cells for 
genes which lose H3K27me3 and gain H3K27ac (n=235) in DKOITD relative to WT BM cells. (F) 
Multidimensional scaling analysis of RNA-seq data from untreated LOUCY and JURKAT cells (n=6 per 
cell line) and DMSO, JQ1 and I-BET151-treated LOUCY cells (n=4 per condition). LOUCY cells treated 
for 24 hr with 0.05% DMSO, 250 nM JQ1 or 500 nM I-BET151. Each point represents one replicate 
sample. (G-I) GSEA comparing DMSO and JQ1-treated LOUCY cells for genes (n=793) showing 
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H3K27ac at the transcription start site in LOUCY but not JURKAT cells (G), genes associated with 
upregulation of KRAS signaling (H), and genes upregulated in DKOITD relative to WT ETPs (left) 
(logFC>2; n=262 genes) and DKOITD relative to WT Mac1+ BM cells (right) (logFC>8; n=219 genes) (I). 
(J) ChIP-qPCR for H3K27me3 and H3K27ac at the Mpl locus in DMSO and UNC1999 (Ezh2 inhibitor) 
treated EML cells (n=3 for each condition). (K) qPCR expression analysis of Mpl mRNA in EML cells 
treated with DMSO, UNC1999, JQ1 or UNC1999 and JQ1 (n=3 for each condition). Bars show mean ± 
SD. p values by T-test, *p<0.05, **p<0.01 and ***p<0.001. See also Figure S7 and Tables S6 and S7. 
 
Figure 8: BET Inhibition Selectively Targets Proliferation of ETP Propagated Leukemia Cells 
(A) MTS proliferation assay of DKOITD ETPs cultured with increasing concentrations of JQ1, relative 
to DMSO control (n=3 for each concentration). (B) Single-cell proliferation assay of CD45.2 Lin-Kit+ 
BM progenitor cells from mice transplanted with WT BM or DKOITD ETP cells and cultured with 
increasing concentrations of JQ1. Frequency of clones showing high proliferation at each 
concentration is shown relative to DMSO control (WT n=3-8 and DKOITD n=4-10 for each 
concentration). Cells were collected from three WT BM and four DKOITD ETP recipient mice. (C) 
White blood cell counts and total BM and spleen cellularity of WT mice transplanted with DKOITD 
BM and treated with 45 mg/kg/day JQ1 or DMSO for 28 days. DMSO n=8, JQ1 n=10. One JQ1 mouse 
was excluded due to weight loss. (D) MTS proliferation assay of K562, LOUCY and THP-1 leukemia 
cell lines with increasing concentrations of JQ1, relative to DMSO control (n=6 for each 
concentration). Data collected from two independent experiments. (E) MTS proliferation assay of T-
ALL and ETP-ALL patient-derived xenografts cultured with increasing concentrations of JQ1, relative 
to DMSO control (n=3 for each concentration). See STAR Methods for mutations carried by ETP-ALL 
samples. (F-G) Peripheral blood chimerism curves (left panels) and white blood cell counts, BM and 
spleen cellularities and human cell composition at end of treatment period (right panels) for NSG 
mice transplanted with human PRC2-mutant ETP-ALLs and treated with 45 mg/kg/day JQ1 or DMSO 
for 36 days. Sample ETP-ALL 12: EZH2 and RUNX1 mutant, DMSO n=8, JQ1 n=8 (F). Sample ETP-ALL 
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13: EED mutant, DMSO n=8, JQ1 n=9 (G). In right panels, fold changes and p values compare 
absolute numbers of human cells. p values by F-test (B, E) or T-test (C, F-G), *p<0.05, **p<0.01 and 
***p<0.001. Bars and horizontal lines show mean ± SEM. See also Figure S8. 
 
STAR Methods 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Adam Mead (adam.mead@imm.ox.ac.uk). 
 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Animal models 
All animal protocols were approved by the UK Home Office. Mice were maintained in individually 
ventilated cages in a specific-pathogen-free facility. Ezh2fl/+, Runx1fl/+, Rag1Cre+ and Flt3ITD/+ mice 
have been previously described (Growney et al., 2005; Lee et al., 2007; McCormack et al., 2003; Su 
et al., 2003). Mx1Cre+ and NSG mice were obtained from the Jackson Laboratory. All mice, except 
NSG recipients, were on a pure C57BL/6 background. Phenotypic analysis was performed on mice 
aged 6-8 weeks unless otherwise stated. Males and females were assigned randomly to control and 
experimental groups. For survival curves, mice that were not analysed were counted as an event. 
 
Patient-derived xenografts 
T-ALL and ETP leukemia patient-derived xenograft samples have been previously described (Maude 
et al., 2015). Genetic lesions carried by ETP leukemia samples: 
Sample no. ID, 
USI/SJCRH 
Age 
(years) 
Gender WBC 
(x109/L) 
Genetic Lesions 
32 
 
ETP-ALL 12 SJTALL165 16 M 251 EZH2 S651L, RUNX1 T148fs, NOTCH1 
S2492*, IKZF1 SV, PHF6 N147fs, SUZ12 
C350R, WT1 C350R L564_S568, SH2B3 SV 
ETP-ALL 13 SJTALL004 3 M 21.5 EED S259F 
 
Cell lines 
EML cells (established from mouse bone marrow) were purchased from ATCC (ATCC number: CRL-
11691). EML cells were cultured in IMDM (Gibco) supplemented with 20% FCS (HyClone), 200 ng/ml 
mSCF (Peprotech) and 1% penicillin/streptomycin (PAA Laboratories). LOUCY cells (established from 
peripheral blood of a 38-year old female) were purchased from ATCC (ATCC number: CRL-2629). 
JURKAT cells (established from peripheral blood of a 14-year old male) were purchased from ATCC 
(ATCC number: TIB-152). LOUCY and JURKAT cells were cultured in RPMI-1640 (Gibco) supplemented 
with 10% FCS (HyClone) and 1% penicillin/streptomycin (PAA Laboratories). 
 
METHOD DETAILS 
Induction of Mx1Cre 
For Mx1Cre-induced deletion of Ezh2 and Runx1, Ezh2fl/flRunx1fl/flMx1Cre+ mice and 
Ezh2fl/flRunx1fl/flMx1Cre- littermate controls were treated at 6-8 weeks of age with 3 doses of 200 μg 
of Poly(IC) (GE Healthcare) at 2-day intervals by intra-peritoneal injection. 
 
RNA sequencing 
ETPs were prepared for RNA-seq using the SMARTer Ultra Low RNA kit for Illumina Sequencing 
(Clontech). One hundred cells were sorted directly into lysis buffer supplemented with RNase 
Inhibitor (Clontech), before preparation of cDNA libraries as directed using 15 cycles of amplification. 
Amplified cDNA libraries were sheared using the Covaris AFA system. The NEBNext DNA Library Prep 
Reagent Set for Illumina (New England Biolabs) was then used to repair ends, adenylate 3’ ends, 
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ligate genomic adaptors and amplify fragments with Genomic DNA Sample Prep oligos (Illumina). 
Samples were sequenced using the Illumina HiSeq 2000 platform, generating 50 bp single-end reads. 
 
Mac1+ BM cells were prepared for RNA-seq using Smart-Seq2 as previously described (Picelli et al., 
2014). One hundred cells were sorted directly into 4 μl of lysis buffer containing 0.2% Triton X-100 
(Sigma-Aldrich), RNase inhibitor (Clontech), 2.5 mM dNTPs (Thermo Fisher) and 2.5 μM oligo-
dT30VN primer (Biomers.net). cDNA was generated using SuperScript II (Invitrogen), pre-amplified 
using KAPA HiFi HotStart ReadyMix (KAPA Biosystems) and purified using Agencourt AMPure XP 
(Beckman Coulter). Tagmentation and library preparation was performed using the Nextera XT DNA 
Library Preparation Kit (Illumina). Samples were sequenced using the Illumina NextSeq 500 platform, 
generating 75 bp paired-end reads. 
 
LOUCY and JURKAT RNA was extracted from 500,000 cells per sample using the RNeasy Mini Kit 
(Qiagen). Ten nanograms of RNA per sample was then prepared for sequencing using Smart-Seq2 as 
for Mac1+ BM cells above, but generating 75 bp single-end reads. For RNA-seq following inhibitor 
treatment, 500,000 cells per sample were first cultured for 24 hours with either 0.05% DMSO, 250 
nM JQ1 (MedChem Express) or 500 nM I-BET151 (Sigma-Aldrich). Cells were cultured in RPMI-1640 
(Gibco) supplemented with 10% FCS (HyClone) and 1% penicillin/streptomycin (PAA Laboratories). 
 
RNA-seq data analysis 
Mouse ETP and Mac1+ BM cell RNA-sequencing reads were aligned to the mouse genome (mm10) 
using Tophat2 (version 2.0.10) (RRID:SCR_013035) and Bowtie2 (version 2.1.00) (RRID:SCR_005476) 
as the underlying aligner. Non-uniquely mapping reads were filtered using samtools (version 0.1.19) 
(RRID:SCR_002105). Read alignments were summarized to gene identifiers using the htseq-count 
tool (version 0.5.4p5) (RRID:SCR_005514) against the mm10 UCSC transcriptome annotation. 
Differential expression analysis was performed using the generalized linear model function of edgeR 
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(version 3.10.4) (RRID:SCR_012802). Genes with fewer than 2 reads in at least 3 samples were 
excluded from subsequent analysis. RPKM value calculation was performed using the rpkm function 
of edgeR. 
 
LOUCY and JURKAT reads were aligned to the human genome (hg38) using STAR (version 2.5.1b) 
(RRID:SCR_004463). Reads mapping to gene exons were counted using the Subread (version 1.4.5-
p1) featureCounts tool (RRID:SCR_009803) and UCSC hg38 annotation. Analysis was performed using 
edgeR (version 3.10.5) (RRID:SCR_012802). Only genes detected at greater than 1 count per million 
(cpm) in at least 4 samples were used for analysis. 
 
Gene set enrichment analysis 
Gene set enrichment analysis was performed using GSEA software (v 2.2.0) (RRID:SCR_003199). The 
Hallmark gene sets were obtained from MSigDB (RRID:SCR_003199) and converted to mouse gene 
identifiers using the Biomart (RRID:SCR_006442) R package prior to analysis. ETP-ALL gene sets were 
derived from the top 500 up- or downregulated genes in ETP-ALL relative to non-ETP T-ALL (Zhang et 
al., 2012a), converted to mouse gene identifiers using Biomart. For ETP-ALL GSEA, previously 
published RNA-seq data was obtained from mouse Notch1 T-ALL (Ntziachristos et al., 2014) and 
wild-type mouse DP thymocytes (Zhang et al., 2012b), and compared to DKOITD Mac1+ BM cells or 
DKOITD ETPs respectively. Custom gene expression signatures for early T cells, myeloid cells and 
HSCs were generated as follows. Previously published data (Luc et al., 2012) (https://gexc.riken.jp/) 
were used to perform differential expression comparisons between ETPs and HSCs, and DN2 and 
HSC (Luc et al., 2012), and between DN1 and HSCs, and GMPs and HSCs (https://gexc.riken.jp/). 
Gene sets up-regulated to each of the following cell types were generated by combining genes from 
the above comparisons as follows: early T cells (ETP against HSC, DN2 against HSC and DN1 against 
HSC); Myeloid (GMPs against HSCs). The early T cell gene set consisted of all genes upregulated in 
early T cells but not myeloid cells, while the myeloid gene set consisted of all genes upregulated in 
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myeloid cells but not early T cells. The HSC gene set consisted of all genes upregulated in HSCs 
relative to any other cell type, and not present in the early T cell or myeloid sets. The PRC2 target 
gene set (De Raedt et al., 2014), Pre-GM and Pre-MegE gene sets (Sanjuan-Pla et al., 2013) have 
been previously described. 
 
Multiplex qPCR 
Multiplex quantitative real time PCR analysis was performed using the BioMark 96.96 Dynamic Array 
platform (Fluidigm) and TaqMan gene expression assays (Life Technologies; see Table S8 for full list 
of assays used). CellsDirect One-Step qRT-PCR kit (Invitrogen) was used for cDNA synthesis and pre-
amplification of target genes. Cells were FACS-sorted directly into 5 μl (single cells) or 10 μl (bulk; 50 
cells) of lysis/pre-amplification buffer. Ten microliters of this buffer consisted of: 2.5 μl Taqman 
assay mix containing all assays at 0.2x dilution, 5 μL CellsDirect 2x Reaction mix (Invitrogen), 1.2 μL 
CellsDirect RT/Taq mix (Invitrogen), 1.2 μL TE buffer and 0.1 μL SUPERase-In RNase Inhibitor 
(Ambion). Reverse transcription and target pre-amplification were performed as follows: 50ºC for 15 
min; 95ºC for 2 min; 22 cycles of 95ºC for 15 s and 60ºC for 4 min. Pre-amplified product was diluted 
1:5 in TE buffer and analyzed using the default M96 RT-PCR protocol. 
 
Single cell qPCR analysis 
Single cell qPCR data analysis was performed in R (version 3.2.2). Cells were filtered so as to only 
retain cells that expressed Actb, B2M, Gapdh and Hprt with Ct values lower than 21. Furthermore at 
least 70 assays were required to result in amplification per cell for it to be included in the analysis. 
Cells with consistently low amplification (mean non drop-out Ct > 20) were excluded from the 
analysis. Absolute expression was calculated as 2-Ct. Ct values were standardized per gene, after 
excluding measurements that did not give rise to any amplification, for the purposes of visualization. 
Significance of differential expression was assessed by means of the Kolmogorov-Smirnov non-
parametric test on the raw Ct values after FDR multiple testing correction. 
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Bulk qPCR analysis 
Bulk qPCR analysis was performed in R (version 3.2.2). Assays with Ct values over 30 and reactions 
that failed quality control by the instrument were excluded. Assays with undetermined values in 
more than two samples were excluded from the analysis. The mean Ct value of technical replicates 
was obtained and used for further analysis. Delta Ct normalization was performed using Gapdh as 
reference. 
 
Whole exome sequencing 
Genomic DNA was extracted from bone marrow cells using the DNeasy Blood & Tissue Kit (Qiagen). 
DNA was prepared for sequencing using the SureSelectXT Mouse All Exon Kit (Agilent). Sequencing 
was performed using the Illumina HiSeq 4000 platform, generating 2x70 bp paired-end reads and an 
average coverage of 103X. 
 
The raw whole-exome sequence data was aligned to GRCm38/mm10 mouse reference genome 
using the BWA-MEM algorithm (v. 0.7.12-r1039) (http://bio-bwa.sourceforge.net/bwa.shtml), and 
data quality was assessed using MultiQC software (v. 1.2) (RRID:SCR_014982). Candidate 
substitutions and insertions/deletions in 8 DKOITD and 10 wild-type control mice were called using 
the CaVEMan (v. 1.7.2) (http://cancerit.github.io/CaVEMan/) and PINDEL (v. 1.5.4) 
(RRID:SCR_000560) algorithms. Orthologous human genes to coding variants identified using this 
method were determined using the Ensembl database (v. 78) (RRID:SCR_002344). The list of 
orthologous human genes to each mouse variant was generated using the “getLDS” function from 
the biomaRt package (v. 2.30.0) (RRID:SCR_006442). The Cancer Gene Census database was used to 
identify variants in DKOITD leukemic mice for which mutations have been causally implicated in 
cancer for their orthologous pair (http://cancer.sanger.ac.uk/census). 
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Copy number alterations were identified using the CNVkit software (v. 0.8.5) 
(http://cnvkit.readthedocs.io/en/stable/) and the “bin-level log2 ratios” (.cnr) and “segmented log2 
ratios” (.cns) results of CNVkit. Segments with log2-ratio >= +0.2 or <= -0.25 were selected as 
candidate copy number gains or losses, respectively. These thresholds are sensitive enough to detect 
single-copy gain or loss in a diploid tumor with as low as 30% sub-clonality (or purity). Genes 
potentially affected by candidate copy number variations were mapped to human orthologs using 
the same approach as for substitutions and insertions/deletions. Using the Cancer Gene Census 
database as for substitutions and insertions/deletions, none of these were identified as causally 
implicated in cancer. 
 
Chromatin immunoprecipitation (ChIP) 
EML cells (ATCC) were cultured in IMDM (Gibco) supplemented with 20% FCS (HyClone), 200 ng/ml 
mSCF (Peprotech) and 1% penicillin/streptomycin (PAA Laboratories). For H3K27me3 and H3K27ac 
ChIP, cells were fixed with 1% formaldehyde for 10 min. Fixed chromatin samples were fragmented 
using an S220 Focused-ultrasonicator (Covaris) to an average size of 200-500 bp. 
Immunoprecipitation was then performed using a mixture of Protein A and Protein G Dynabeads 
(Life Technologies). Antibodies used were: anti-H3K27me3 (07-449, Merck MilliPore) and anti-
H3K27ac (C15410196, Diagenode). ChIP samples were quantified relative to inputs as previously 
described (Milne et al., 2009). Three replicate samples were used for ChIP-qPCR. See Key Resources 
Table for primer sequences used. 
 
For WT and DKOITD bone marrow ChIP-seq, three samples of WT and five samples of DKOITD, each 
sample consisting of cells from separate mice, were used. WT samples were first enriched for Kit 
expressing cells using CD117 microbeads and LS columns (Miltenyi Biotec) as directed. 5 million cells 
per sample were used for ChIP-seq, which was performed using conditions and antibodies as for 
H3K27ac and H3K27me3 ChIP in EML cells (above). One input control sample was used for each 
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genotype. Samples were prepared for sequencing using the NEBNext Ultra II DNA Library Prep Kit for 
Illumina, with NEBNext Multiplex Oligos for Illumina (New England BioLabs) as directed. Sequencing 
was performed using the Illumina NextSeq 500 platform, generating 40 bp paired-end reads. 
 
For ChIP-qPCR and gene expression analysis of EML C1 cells, cells were treated with DMSO or 5 μM 
UNC1999 (Cambridge Bioscience) and/or 250 nM JQ1 (MedChem Express) for 48 hr before 
harvesting. RNA was extracted using RNeasy Mini Kit (Qiagen), and cDNA generated using 
SuperScript II (Invitrogen) as directed. Expression of Mpl was quantified and shown normalised to 
Actb using custom primers (see Key Resources Table) and SYBR Green (Thermo-Fisher) and the ddCt 
method. 
 
ChIP-seq data analysis 
For WT and DKOITD ChIP-seq analysis, reads were aligned to the mouse genome (mm10) using 
Bowtie2 (version 2.2.5) (RRID:SCR_005476). Peak calling was performed using Macs2 (version 2.0.10) 
(RRID:SCR_013291) and the broad peak calling parameter. DiffBind (version 1.14.6) 
(RRID:SCR_012918) was used to identify regions under peaks called by Macs2 which were associated 
with significantly different levels of H3K27ac and H3K27me3 in DKOITD versus WT samples. Tracks 
for genome visualisation were generated using the Macs2 bdgcmp function and the UCSC genome 
browser (http://genome.ucsc.edu/). Identified peaks and regions showing differential H3K27ac and 
H3K27me3 were mapped to nearby transcription start sites (within 2.5kb in either direction) using 
Homer (version 4.7) (RRID:SCR_010881). Normalised read density histograms and heatmaps were 
generated using Homer, by pooling reads from replicate WT and DKOITD samples. Genes showing 
reduced H3K27me3 in DKOITD were obtained from the DiffBind analysis of individual samples. 
 
For LOUCY and JURKAT ChIP-seq analysis, reads were aligned to the human genome (hg38) using 
Bowtie2 (version 2.2.5) (RRID:SCR_005476). Peak calling was performed using Macs2 (version 2.0.10) 
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(RRID:SCR_013291) and the broad peak calling parameter. Identified peaks were mapped to nearby 
transcription start sites (within 1kb in either direction) using Homer (version 4.7) (RRID:SCR_010881) 
and hg38 annotation data (NCBI RefSeq Curated) downloaded from the UCSC Table Browser 
(RRID:SCR_005780). 
 
Histology and immunohistochemistry 
Mouse tissue was fixed in neutral buffered formalin and processed to paraffin using standard 
techniques. Three-micron sections were cut and stained with hematoxylin and eosin. Serial sections 
were immunostained for CD3 using polyclonal rabbit serum raised against a synthetic peptide 
corresponding to a region showing 100% homology between mouse and human CD3ε at the 
manufacturer’s “ready-to-use” concentration (IR503; Dako). Immunostaining for TdT was performed 
using polyclonal rabbit anti-TdT (ab85148; Abcam) at a 1:200 dilution. Staining was performed on a 
Ventana Discovery Ultra Immunostainer (Ventana Medical Systems). Briefly, following 
deparaffinisation, sections were heated to 95ºC for 36 min in CC1 solution (a tris-based buffer with 
slightly alkaline pH) and incubated in primary antibody at 36ºC for 32 min. Bound rabbit antibody 
was detected using the Omnimap anti-rabbit DAB kit. All reagents apart from the primary antibody 
were obtained from Ventana Medical Systems and used according to the manufacturer’s 
instructions. Immunostaining of WT mouse thymus was used as a positive control for both CD3 and 
TdT. Rabbit anti-FITC antibody (71-1900; Life Technologies) was used as a negative control on 
representative histological sections. Stained sections were photographed with a Nikon DS-FI1 
camera with a Nikon DS-L2 control unit and an Olympus BX40 microscope. 
 
Phospho-flow cytometry 
Unfractionated bone marrow cells were cultured in Opti-MEM (Gibco), 5 million cells per ml, without 
serum or cytokines for 2 hours. For MEK inhibitor experiments, either 0.05% DMSO or 2.5 μM PD-
901 (PD0325901; Cambridge Biosciences) were added to the media. Cells were then fixed with 1.5% 
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paraformaldehyde (Electron Microscopy Sciences) for 10 minutes at 22ºC. Fixed cells were treated 
with Fc block and stained for Sca1 (Pacific Blue conjugate), then permeabilised with ice-cold acetone 
for 15 minutes before staining for phospho-S6 (APC), Kit (APC-eF780) and lineage markers (B220, 
Ter119, Mac1 and Gr1, all conjugated to PE-Cy5). Lin-Kit+ cells were gated for analysis of phospho-S6. 
 
In vitro proliferation assays 
For granulocyte-monocyte assays, 75 ETPs were sorted into 1.5 ml of X-Vivo 15 (SLS Life Science) 
supplemented with 10% FCS (HyClone), 10-4 M 2-mercaptoethanol (Sigma-Aldrich), 1% 
penicillin/streptomycin (PAA Laboratories) and the following cytokines: 2 ng/ml murine stem cell 
factor (mSCF; PeproTech), 5 ng/ml human FLT3 ligand (hFL; Immunex), 5 ng/ml human 
thrombopoietin (hTPO; PeproTech), 5 ng/ml murine interleukin 3 (mIL-3; PeproTech), 10 ng/ml 
human granulocyte colony-stimulating factor (G-CSF; Neopogen) and 10 ng/ml murine granulocyte-
macrophage colony-stimulating factor (mGM-CSF; Immunex). Twenty microliters were transferred to 
each well of a 60-well Terasaki plate (VWR), seeding on average one cell per well by Poisson 
distribution. Density of cell growth in each well was evaluated after 8 days of culture. 
 
For colony assays, single cells were sorted directly into 60-well Terasaki plates containing media as 
defined above and including either 0.05% DMSO or equivalent volumes of JQ1 (MedChem Express) 
or I-BET151 (Sigma-Aldrich) to final concentrations as indicated. Density of cell growth in each well 
was evaluated after 8 days of culture, with each well containing a colony derived from a single cell. 
Colonies of 50 cells or more were defined as highly proliferative. The proportion of wells containing 
highly proliferative colonies for one 60-well plate was used as a single replicate. 
 
For MTS assays, 500 cells (ETPs), 20,000 cells (cell lines) or 250,000 cells (patient-derived xenografts) 
were cultured in 100 μl of media (see below) in 96-well plates for 72 hours (ETPs and cell lines) or 48 
hours (xenografts) before measuring proliferation using the CellTiter 96 AQueous Non-Radioactive 
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Cell Proliferation Assay (Promega) as directed. For ETPs, media consisted of Opti-MEM (Gibco) 
supplemented with 10% FCS (HyClone), 10-4 M 2-mercaptoethanol (Sigma-Aldrich), 1% 
penicillin/streptomycin (PAA Laboratories) and the following cytokines: 10 ng/ml mSCF (PeproTech), 
5 ng/ml hFL (Immunex), 10 ng/ml hTPO (PeproTech), 20 ng/ml mIL-3 (PeproTech), 20 ng/ml hG-CSF 
(Neopogen), 20 ng/ml mGM-CSF (Immunex) and 10 ng/ml human colony stimulating factor 1 (hCSF1; 
Cetus). For cell lines, media consisted of RPMI-1640 (Gibco) supplemented with 10% FCS (HyClone) 
and 1% penicillin/streptomycin (PAA Laboratories). For patient-derived xenografts, media consisted 
of RPMI-1640 (Gibco) supplemented with 10% FCS (HyClone), 1% penicillin/streptomycin (PAA 
Laboratories), 10 ng/ml hSCF (PeproTech), 10 ng/ml hFL (Immunex), 10 ng/ml hTPO (PeproTech), 10 
ng/ml hG-CSF (Neopogen), 10 ng/ml hGM-CSF (Berlex), 10 ng/ml hIL-6 (PeproTech) and 10 ng/ml hIL-
7 (PeproTech). Either 0.05% DMSO or equivalent volumes of JQ1 (MedChem Express) or I-BET151 
(Sigma-Aldrich) were added to final concentrations as indicated. 
 
Patient-derived xenograft cells were obtained from spleens of leukemic recipient mice (Maude et al., 
2015). FACS analysis was used to confirm >85% human chimerism of CD45+ cells before cells were 
used for MTS assays. 
 
In vivo experiments 
For thymocyte transplantation experiments, C57BL/6 CD45.1 recipient mice were lethally irradiated 
(10 Gy, split dose) before intra-venous transplantation of total numbers of each specified population 
in the thymus: ETPs (range 413-6880 cells), DN2 (range 557-8005 cells) or DP/SP (range 412-1462 
cells) with 250,000 CD45.1 unfractionated bone marrow support cells. Analysis of hematological 
parameters was performed using a Sysmex KX-21N analyser. Presence of leukemia was arbitrarily 
defined as a white blood cell count > 50x109/L in the peripheral blood or blast percentage in the 
peripheral blood and/or bone marrow greater than 20%. 
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In vivo administration of JQ1 
C57BL/6 CD45.1 recipient mice were lethally irradiated (10 Gy, split dose) before intra-venous 
transplantation of 2 million DKOITD bone marrow cells with 500,000 CD45.1 unfractionated bone 
marrow support cells. NSG mice were sublethally irradiated (2.5 Gy, split dose) before injection of 2-
2.5 million ETP-ALL xenograft spleen cells. For in vivo treatment, a 100 mg/ml stock of JQ1 
(MedChem Express) in DMSO was diluted 1/20 into 10% 2-hydroxypropyl-β-cyclodextrin (Cambridge 
Bioscience), and administered daily by intra-peritoneal injection at a dose of 45 mg/kg. Control mice 
received a similar volume of diluted DMSO. Each mouse received a maximum of 36 intra-peritoneal 
injections as specified by Home Office approvals. Analysis of hematological parameters was 
performed using a Sysmex KX-21N analyser. 
 
In vivo administration of I-BET151 
C57BL/6 CD45.1 recipient mice were sub-lethally irradiated (a single dose of 5.5 Gy) before intra-
venous transplantation of approximately 1.8 million DKOITD bone marrow cells re-suspended in 
Hanks' Balanced Salt Solution (Sigma). Peripheral blood was collected from the saphenous vein into 
EDTA-coated tubes (Sarstedt). Analysis of hematological parameters was performed using a Vet abc 
counter (Scil Animal Care). These in vivo studies used a modified murine feed containing 0.018% 
(180ppm) I-BET151 (or control feed). All mice had ad libitum access to feed. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Details of statistical tests are indicated in the Figure Legends. Statistical analyses were performed 
using GraphPad Prism v7.00 or R v3.2.2. Survival curves were compared using the log-rank test. The 
T-test or ANOVA followed by multiple comparisons testing were used to compare experimental 
groups as indicated in the Figure Legends. Sensitivity of experimental groups to JQ1 and I-BET151 in 
in vitro proliferation assays was compared using the F-test after fitting curves to the data. Numbers 
of replicates for each experiment are indicated in the Figure Legends. 
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Significance of overlap of genes showing reduced H3K27me3 and increased H3K27ac with genes 
showing upregulated expression was assessed using the R “phyper” function. The number of genes 
detected in either genotype by RNA-sequencing (11,172) was used as the total number of genes. 
 
DATA AND SOFTWARE AVAILABILITY 
GEO codes: GSE75185 (ETP RNA-seq), GSE75187 (bone marrow Mac1+ cell RNA-seq), GSE100693 
(bone marrow and human cell line ChIP-seq), GSE100694 (human cell line RNA-seq). 
 
Supplemental Tables 
Table S1, Related to Figure 2. ETP RNA-seq data for DKO vs WT (RPKMs, fold changes and 
significance). Provided as an Excel file. 
 
Table S2, Related to Figure 2. Hallmark GSEA for DKO ETPs. Provided as an Excel file. 
 
Table S3, Related to Figure 4. Cancer-associated substitutions and insertions/deletions, and copy 
number variants detected by exome sequencing of DKOITD leukemia samples. Provided as an Excel 
file. 
 
Table S4, Related to Figure 6. ETP RNA-seq data for DKOITD vs WT and DKOITD vs DKO (RPKMs, fold 
changes and significance). Provided as an Excel file. 
 
Table S5, Related to Figure 6. Hallmark GSEA for DKOITD ETPs. Provided as an Excel file. 
 
Table S6, Related to Figure 7. Overlaps of genes showing differential H3K27ac and H3K27me3 with 
differential expression in DKOITD relative to WT bone marrow cells. Provided as an Excel file. 
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Table S7, Related to Figure 7. Hallmark GSEA for LOUCY cells: JQ1 vs DMSO and I-BET151 vs DMSO. 
Provided as an Excel file. 
 
Table S8, Related to STAR Methods. List of Taqman probes used for gene expression analysis of ETPs. 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
B220 APC BioLegend Clone RA3-6B2, Cat# 
103211 
B220 PE-Cy5 BioLegend Clone RA3-6B2, Cat# 
103209 
B220 PE-Texas Red Becton Dickinson Clone RA3-6B2, Cat# 
551489 
CD11c APC eBioscience Clone N418, Cat# 
17-0114-81 
CD150 PE-Cy7 BioLegend Clone TC15-12F12.2, 
Cat# 115913 
CD19 APC eBioscience Clone 1D3, Cat# 17-
0193-82 
CD19 PE-Cy7 eBioscience Clone 1D3, Cat# 25-
0193-82 
CD25 PerCP-Cy5.5 BioLegend Clone PC61, Cat# 
102029 
CD3e APC eBioscience Clone 145-2C11, 
Cat# 17-0031-82 
CD4 AF700 eBioscience Clone RM4-5, Cat# 
56-0042-82 
CD4 APC-eF780 eBioscience Clone RM4-5, Cat# 
47-0042-82 
CD4 PE-Cy5 BioLegend Clone RM4-5, Cat# 
100513 
CD44 FITC eBioscience Clone IM7, Cat# 11-
0441-82 
CD45.1 FITC BioLegend Clone A20, Cat# 
110705 
CD45.2 AF700 BioLegend Clone 104, Cat# 
109821 
Key Resource Table
CD48 APC BioLegend Clone HM48-1, Cat# 
103411 
CD5 FITC Becton Dickinson Clone 53-7.3, Cat# 
553024 
CD5 PE-Cy5 BioLegend Clone 53-7.3, Cat# 
100609 
CD8a APC-eF780 eBioscience Clone 53-6.7, Cat# 
47-0081-82 
CD8a PE-Cy7 eBioscience Clone 53-6.7, Cat# 
25-0081-82 
CD8a PE-Cy5 BioLegend Clone 53-6.7, Cat# 
100709 
Flt3 PE BioLegend Clone A2F10, Cat# 
135305 
Gr1 Pacific Orange Invitrogen Clone RB6-8C5, Cat# 
RM3030 
Gr1 PE-Cy5 BioLegend Clone RB6-8C5, Cat# 
108409 
Gr1 APC BioLegend Clone RB6-8C5, Cat# 
108411 
Human CD45 AF700 BioLegend Clone HI30, Cat# 
304023 
Kit APC eBioscience Clone 2B8, Cat# 17-
1171-82 
Kit APC-eF780 eBioscience Clone 2B8, Cat# 47-
1171-82 
Mac1 AF700 eBioscience Clone M1/70, Cat# 
56-0112-82 
Mac1 APC BioLegend Clone M1/70, Cat# 
101211 
Mac1 FITC eBioscience Clone M1/70, Cat# 
11-0112-82 
Mac1 PE eBioscience Clone M1/70, Cat# 
12-0112-82 
Mac1 PE-Cy5 BioLegend Clone M1/70, Cat# 
101209 
Mouse CD45 PE-Texas Red Invitrogen Clone 30-F11, Cat# 
MCD4517 
NK1.1 APC eBioscience Clone PK136, Cat# 
17-5941-82 
NK1.1 Pacific Blue BioLegend Clone PK136, Cat# 
108721 
Phospho-S6 APC Cell Signaling Clone D57.2.2E, Cat# 
14733 
Sca1 BV605 BioLegend Clone D7, Cat# 
108133 
Sca1 Pacific Blue BioLegend Clone E13-161.7, 
Cat# 122519 
Ter119 PE-Cy5 BioLegend Clone TER-119, Cat# 
116209 
H3K27me3 (ChIP) Merck MilliPore Cat# 07-449 
H3K27ac (ChIP) Diagenode Cat# C15410196 
CD3 (Immunohistochemistry) Dako Cat# IR503 
TdT (Immunohistochemistry) Abcam Cat# ab85148 
Bacterial and Virus Strains  
Biological Samples   
Patient-derived xenografts Laboratory of David T. 
Teachey (Maude et 
al., 2015) 
N/A 
Chemicals, Peptides, and Recombinant Proteins 
Poly(IC) GE Healthcare Cat# 27-4732-01 
PD-901 Cambridge Bioscience Cat# SM26 
JQ1 MedChem Express Cat# HY-13030 
I-BET151 Sigma-Aldrich Cat# SML0666 
2-hydroxypropyl-β-cyclodextrin Cambridge Bioscience Cat# CAY16169 
Critical Commercial Assays 
SMARTer Ultra Low RNA kit for Illumina Sequencing Clontech Cat# 634936 
NEBNext DNA Library Prep Reagent Set for Illumina New England Biolabs Cat# E6000 
Nextera XT DNA Library Preparation Kit Illumina Cat# FC-131 
CellsDirect One-Step qRT-PCR kit Invitrogen Cat# 11753100 
SureSelectXT Mouse All Exon Kit Agilent Cat# 5190-4641 
NEBNext Ultra II DNA Library Prep Kit for Illumina New England BioLabs Cat# E7645 
Deposited Data 
ETP RNA-seq This paper GSE75185 
Mac1+ bone marrow RNA-seq This paper GSE75187 
Mouse bone marrow, LOUCY and JURKAT ChIP-seq This paper GSE100693 
LOUCY and JURKAT RNA-seq This paper GSE100694 
Experimental Models: Cell Lines 
Mouse: EML ATCC ATCC number: CRL-
11691 
Human: LOUCY ATCC ATCC number: CRL-
2629 
Human: JURKAT ATCC ATCC number: TIB-
152 
Experimental Models: Organisms/Strains 
Mouse: C57BL/6 Ezh2fl/+ (Su et al., 2003) N/A 
Mouse: C57BL/6 Runx1fl/+ (Growney et al., 2005) N/A 
Mouse: C57BL/6 Mx1Cre The Jackson 
Laboratory 
Cat# 003556 
Mouse: C57BL/6 Rag1Cre (McCormack et al., 
2003) 
N/A 
Mouse: C57BL/6 Flt3ITD/+ (Lee et al., 2007) N/A 
Mouse: NSG The Jackson 
Laboratory 
Cat# 005557 
Oligonucleotides 
EML cell H3K27ac and H3K27me3 ChIP-qPCR: Mpl 
forward primer: GCAACGTGGAGTGGGTCT 
This paper N/A 
EML cell H3K27ac and H3K27me3 ChIP-qPCR: Mpl 
reverse primer: GCTGTGTGTGTGTTCCTCGT 
This paper N/A 
EML cell gene expression qPCR: Mpl forward primer: 
CTGTATGCCTACCGAGGAGAG 
This paper N/A 
EML cell gene expression qPCR: Mpl reverse primer: 
TCTGGTTGAGGGACACATTCTT 
This paper N/A 
EML cell gene expression qPCR: Actin forward primer: 
GGCTGTATTCCCCTCCATCG 
This paper N/A 
EML cell gene expression qPCR: Actin reverse primer: 
CCAGTTGGTAACAATGCCATGT 
This paper N/A 
For Taqman probes used for gene expression analysis 
see Table S8. 
N/A N/A 
Recombinant DNA 
Software and Algorithms 
Flowjo Treestar RRID:SCR_008520 
Tophat2 John Hopkins 
University 
RRID:SCR_013035 
Bowtie2 University of 
California Santa Cruz 
RRID:SCR_005476 
Samtools Wellcome Trust 
Sanger Institute 
RRID:SCR_002105 
HTseq EMBL Heidelberg RRID:SCR_005514 
edgeR Walter and Eliza Hall 
Institute of Medical 
Research 
RRID:SCR_012802 
STAR Cold Spring Harbor 
Laboratory 
RRID:SCR_004463 
Subread Walter and Eliza Hall 
Institute of Medical 
Research 
RRID:SCR_009803 
Gene set enrichment analysis Broad Institute RRID:SCR_003199 
MSigDB Broad Institute RRID:SCR_003199 
Gene expression commons Stanford University https://gexc.riken.jp
/ 
BWA-MEM Broad Institute http://bio-
bwa.sourceforge.net
/bwa.shtml 
MultiQC Stockholm University RRID:SCR_014982 
CaVEMan Wellcome Trust 
Sanger Institute 
http://cancerit.githu
b.io/CaVEMan/ 
PINDEL Wellcome Trust 
Sanger Institute 
RRID:SCR_000560 
Ensembl database EMBL-EBI RRID:SCR_002344 
Bioconductor BiomaRt Lawrence Berkeley 
National Laboratory 
RRID:SCR_006442 
Cancer Gene Census Wellcome Trust 
Sanger Institute 
http://cancer.sanger
.ac.uk/census 
CNVkit University of 
California San 
Francisco 
http://cnvkit.readth
edocs.io/en/stable/ 
Macs2 Dana Farber Cancer 
Institute 
RRID:SCR_013291 
DiffBind University of 
Cambridge 
RRID:SCR_012918 
Homer Salk Institute RRID:SCR_010881 
UCSC Table Browser University of 
California Santa Cruz 
RRID:SCR_005780 
Other 
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Figure S1, Related to Figure 1. Inactivation of Ezh2 and Runx1 Targeted to Early Lymphoid Progenitors 
Collaborate to Cause a Marked Expansion of ETPs 
(A) Disease-free survival curves (left) and hematological parameters of peripheral blood at time of culling 
(right) for Ezh2fl/flRunx1fl/flMx1Cre- and Ezh2fl/flRunx1fl/flMx1Cre+ mice treated with Poly(IC) to activate 
Mx1Cre at 6-8 weeks of age. Time on the x-axis represents age of the mice. Significance was tested using 
the log-rank test (left) or T-test (right). Hematological parameters from one mouse are excluded; this mouse 
developed a CD19+Mac1+ leukemia at 42 weeks of age. (B) Determination of efficiency of deletion by 
Rag1Cre of conditionally targeted Ezh2 and Runx1 alleles, in Lin-Kit+Sca1+CD150+CD48- HSCs and Lin-
CD4-CD8-CD44+CD25-Kit+Flt3+ ETPs from 6-8 week old WT and DKO mice. Relative expression levels of 
Ezh2 and Runx1 mRNA are shown; Ct values were normalised to Gapdh. Amplicons were designed to 
target exons removed by Rag1Cre recombination. The bottom panel shows expression of Actb normalised 
to Gapdh. n=4 for each cell type; each replicate represents a sample of 50 cells. Box plots show median, 
upper and lower quartiles. (C) Representative FACS plots showing ETP gating strategy for Ezh2-KO and 
Runx1-KO thymuses. Figures represent mean percentage of total thymocytes falling into each gate across 
all experiments. (D) FACS analysis of absolute numbers of DN2, DN3, DN4 and DP cells per thymus in 6-8 
week old mice (WT n=26, Ezh2-KO n=9, Runx1-KO n=10, DKO n=18). (E) FACS analysis of absolute 
numbers of ETPs per thymus (top) and total thymus cellularity (bottom) in 6 month old mice (WT n=3, DKO 
n=3). p values are by T-test (A, E), or ANOVA (B, D), *p<0.05, **p<0.01 and ***p<0.001. n.s.; not significant 
(p>0.05). Horizontal lines show mean ± SEM (A, D-E). 
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p value color scale 
10-3 > 10-5 10-5 > 10-7 
10-7 > 10-9 < 10-9 
J 
Figure S2, Related to Figure 2. Disrupted Gene Expression Signatures in DKO ETPs Recapitulate 
Features of ETP Leukemia 
(A) Hierarchical clustering and heatmap showing expression levels, scaled per gene, of the 3000 most 
variable genes between WT and DKO ETPs (WT n=4, DKO n=4). Each replicate represents 100 purified 
ETPs from individual mice at 6-8 weeks of age. (B-D) GSEA plots of HSC (B), Pre-GM (C) and Pre-MegE 
gene expression programs (D) comparing WT and DKO ETPs. (E-G) Relative expression level of  HSC (E), 
myeloid (F) and lymphoid-associated genes (G) in DKO ETPs expressed relative to the level in WT ETPs 
(log2 scale) as determined by qPCR (WT n=8, DKO n=7). Each replicate represents 50 purified ETPs from 
individual mice at 6-8 weeks of age. Bars show mean ± SD. (H) Gene ontology diagram showing pathways 
enriched in DKO relative to WT ETPs. (I-J) GSEA plots comparing WT and DKO ETPs for Interferon 
signaling target genes (I) (Interferon gamma left panel and Interferon alpha right panel) and Notch1 target 
genes (J). 
  

Figure S3, Related to Figure 3. HSC and Myeloid Genes are Co-Expressed within Single DKO ETPs. 
Scatter plot showing level of co-expression of HSC and myeloid genes within single WT (n=129) and DKO 
(n=91) ETPs. Each dot represents a single cell, for which are plotted the number of genes showing 
detectable expression from the panel of HSC- and myeloid-associated genes shown in Figure 3A. 
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Figure S4, Related to Figure 4. Activating Flt3 Mutation Collaborates with Inactivating Ezh2 and Runx1 
Mutations Targeted to Early Lymphoid Progenitors to Cause Acute Leukemia 
(A) Total spleen cellularity in 6-8 week old WT (n=4), DKO (n=3), ITD (n=6) mice and leukemic DKOITD 
(n=4) mice. (B) Morphology of peripheral blood leukocytes in leukemic DKOITD (n=3) and littermate ITD 
control (n=3) mice. One hundred cells were scored according to morphology for each sample. Bars show 
mean ± SEM. (C) Overview of analysis of data from exome sequencing of DKOITD leukemias. Genomic 
DNA was extracted from bone marrow cells of 8 DKOITD leukemic mice, 2 WT mice from the same colony, 
and 8 WT mice from an unrelated C57BL/6 colony. (D) Total cellularity and FACS analysis of absolute 
numbers of Kit+Mac1low (myeloid precursor cells) per femur and tibia from 6-8 week old WT (n=9), DKO 
(n=5), ITD (n=4) mice and leukemic DKOITD (n=4) mice. (E) Representative FACS plots showing lack of 
co-expression of Mac1 with surface CD3 (left panels) and positive co-expression of CD5 with surface CD3 
(right panels) in both WT and leukemic DKOITD bone marrow. Figures represent the mean percentage of 
total bone marrow cells falling into each gate across all experiments. (F) Expression relative to WT of 
leukemia oncogenes in leukemic DKOITD Mac1+ BM cells (WT n=3, DKOITD n=4). p values are by 
ANOVA, *p<0.05, **p<0.01 and ***p<0.001. n.s.; not significant (p>0.05). Horizontal lines show mean ± 
SEM (A, D). 
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Figure S5, Related to Figure 5. Leukemia Induced by Activating Flt3 Mutation Combined with Inactivating 
Runx1 and Ezh2 Mutations can be Propagated by ETPs 
(A) Representative peripheral blood smear and bone marrow cytospin images from a leukemic DKOITD 
ETP transplant recipient. Scale bars represent 20 μm. (B) Representative FACS plots showing relative 
contribution of CD45.1 and CD45.2 cells to thymocyte populations in moribund DKOITD ETP-transplant 
recipient mice. Figures represent the mean percentage of total thymocytes falling into each gate across all 
replicates. 
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Figure S6, Related to Figure 6. Activating Flt3 Mutation Augments Upregulation of Signaling Pathway-
Associated Transcription in Ezh2 and Runx1-Inactivated ETPs 
(A) Hierarchical clustering and heatmap showing expression levels, scaled per gene, of the 3000 most 
variable genes between WT, DKO and DKOITD ETPs (WT n=4, DKO n=4, DKOITD n=4). Each replicate 
represents 100 purified ETPs from individual mice at 6-8 weeks of age. (B-C) Expression relative to WT of 
myeloid (B) and HSC-associated genes (C) in DKO and DKOITD ETPs as determined by qPCR (WT n=8, 
DKO n=7, DKOITD n=6). Box plots show median, lower and upper quartiles. Replicates shown as dots 
when outside 1.5 times the inter-quartile range. (D) Principal component analysis of single-cell qPCR data 
from WT HSCs (n=20), LMPPs (n=36) and ETPs (n=129), DKO HSCs (n=33), LMPPs (n=31) and ETPs 
(n=91), and DKOITD LMPPs (n=33) and ETPs (n=122). Cells were collected from 12 WT, 9 DKO and 8 
DKOITD mice. (E) GSEA comparing WT DP thymocytes and DKOITD ETPs for genes downregulated in 
human ETP-ALL relative to non-ETP T-ALL. 
  
A B 
C 
D 
E F 
Sample
H3K27ac 
Peaks
H3K27me3 
Peaks
LOUCY-1 28969 180
LOUCY-2 39438 190
JURKAT-1 31969 13455
JURKAT-2 29064 8386
Figure S7, Related to Figure 7. BET Inhibition Reverses Gene Expression Changes Associated with Loss 
of PRC2 Function 
(A) Cluster dendrograms and correlation between replicates of WT and DKOITD bone marrow ChIP-seq 
samples, comparing normalised read density at each H3K27ac (top) and H3K27me3 (bottom) peak 
location. (B) Heatmaps showing normalised read density of H3K27me3 and H3K27ac at the transcription 
start site for all genes showing significantly decreased H3K27me3 in DKOITD relative to WT bone marrow 
cells (n=520 genes). Tracks are centred on the transcription start site and extend 2 kb upstream (left) and 2 
kb downstream (right). Genes are ordered separately for H3K27me3 and H3K27ac by average intensity in 
WT. (C) Genome browser tracks showing H3K27me3 and H3K27ac at the Enah and Rras2 loci in WT and 
DKOITD bone marrow cells. Fold change refers to gene expression in DKOITD relative to WT Mac1+ BM 
cells. (D) Experimental design for ChIP-seq and RNA-seq experiments in LOUCY and JURKAT cells. ChIP-
seq n=2 per cell line per histone mark, RNA-seq n=6 per cell line (untreated cells) and n=4 per condition 
(DMSO, JQ1 and I-BET151-treated LOUCY cells). (E) GSEA comparing LOUCY and JURKAT cells for 
genes upregulated (left) or downregulated (right) in human ETP-ALL relative to non-ETP T-ALL. (F) RPKM 
expression levels of EZH2 (left), and number of peaks detected genome-wide per sample for H3K27ac and 
H3K27me3 (right) in LOUCY and JURKAT cells. 
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Figure S8, Related to Figure 8. BET Inhibition Selectively Targets Proliferation of ETP Propagated 
Leukemia Cells 
(A) Single-cell proliferation assay of DKOITD ETPs cultured with increasing concentrations of JQ1. 
Frequency of clones showing high proliferation at each concentration is shown relative to DMSO control 
(n=3-5 for each concentration). (B) MTS proliferation assay of leukemia cell lines cultured with increasing 
concentrations of JQ1, shown relative to DMSO control (n=6 for each concentration). Data were collected 
across two independent experiments. (C) Single-cell proliferation assay of CD45.2 Lin-Kit+ BM progenitor 
cells FACS-sorted from recipient mice transplanted with WT BM or DKOITD ETP cells and cultured with 
increasing concentrations of I-BET151. Frequency of clones showing high proliferation at each 
concentration is shown relative to DMSO control (WT n=3-5 and DKOITD n=4-8 for each concentration). 
Data were collected from two WT BM and four DKOITD ETP recipient mice. (D) White blood cell counts, 
total BM cellularity and spleen weights of wild-type mice transplanted with DKOITD bone marrow and 
administered modified murine feed containing 0.018% (180ppm) I-BET151 or control feed. Control n=9, I-
BET151 n=9. (E) MTS proliferation assay of K562, LOUCY and THP-1 leukemia cell lines cultured with 
increasing concentrations of I-BET151, shown relative to DMSO control. Data were collected across two 
independent experiments. (F) MTS proliferation assay of T-ALL and ETP-ALL patient-derived xenografts 
cultured with increasing concentrations of I-BET151, shown relative to DMSO control (n=3 for each 
concentration). See STAR Methods for mutations carried by ETP-ALL samples. p values are by F-test (C, 
F) or T-test (D), *p<0.05, **p<0.01 and ***p<0.001. n.s.; not significant (p>0.05). Horizontal lines show 
mean ± SEM. 
Table S8, Related to STAR Methods. List of Taqman probes used for gene expression analysis of ETPs. 
Target gene Assay ID 
Actb Mm00607939_s1 
Anxa1 Mm00440225_m1 
Arpp21 Mm00473630_m1 
B2M Mm00437762_m1 
Bcl11a Mm00479358_m1 
Bmi1 Mm03053308_g1 
Ccl9 Mm00441260_m1 
Ccr7 Mm01301785_m1 
Ccr9 Mm02620030_s1 
Cd160 Mm00444461_m1 
Cebpb Mm00843434_s1 
Cish Mm01230623_g1 
Cited2 Mm01188099_g1 
Cpa3 Mm00483940_m1 
Csf1r Mm01266652_m1 
Csf2ra Mm00438331_g1 
Csf3r Mm00432735_m1 
Ctsc Mm00515580_m1 
Ctsg Mm00456011_m1 
Cxcr4 Mm01996749_s1 
Dtx1 Mm00492297_m1 
Dyrk1a Mm00432934_m1 
Erg Mm01214246_m1 
Esam Mm00518378_m1 
Etv6 Mm00468390_m1 
Ezh2 - WT and Deleted Mm00468449_m1 
Ezh2 - WT only Mm00468464_m1 
F2r Mm00438851_m1 
Fcer1g Mm02343757_m1 
Fcgr3 Mm00438882_m1 
Fes Mm01318102_m1 
Fli1 Mm00484410_m1 
Flt3 Mm01210882_m1 
Fos Mm00487425_m1 
Gapdh Mm99999915_g1 
Gata2 Mm00492301_m1 
Gata3 Mm00484683_m1 
Gfi1 Mm00515855_m1 
Gfi1b Mm00492318_m1 
Hes1 Mm01342805_m1 
Hey1 Mm00468865_m1 
Hlf Mm00723157_m1 
Hoxa9 Mm00439364_m1 
Hprt Mm01545399_m1 
Id1 Mm00775963_g1 
Id2 Mm00711781_m1 
Igf2r Mm00439576_m1 
Ikzf1 Mm01187882_m1 
Il2ra Mm00434261_m1 
Il3ra Mm00434273_m1 
IL4 Mm00445259_m1 
Il7r Mm00434295_m1 
Itgam Mm00434455_m1 
Jag1 Mm00496902_m1 
Jun Mm00495062_s1 
Kit Mm00445212_m1 
Lat Mm00456761_m1 
Lck Mm00802897_m1 
Lef1 Mm00550265_m1 
Lmo2 Mm01281680_m1 
Ly6a Mm00726565_s1 
Ly6d Mm00521959_m1 
Lyz1 Mm00657323_m1 
Lyz2 Mm01612741_m1 
Mcl1 Mm00725832_s1 
Mef2c Mm01340842_m1 
Meis1 Mm00487664_m1 
Mpl Mm00440310_m1 
Mpo Mm01298424_m1 
Ms4a6b Mm00728225_m1 
Ms4a6c Mm00459296_m1 
Myb Mm00501741_m1 
Myc Mm00487804_m1 
Mycn Mm00476449_m1 
Nfe2 Mm00801891_m1 
Notch1 Mm00435249_m1 
Nrarp Mm00482529_s1 
Pbx1 Mm04207617_m1 
Pecam1 Mm01242584_m1 
Pim1 Mm00435712_m1 
Pim2 Mm00454579_m1 
Prkcd Mm00440891_m1 
Ptcra Mm00478363_m1 
Rag1 
  
  
  
Custom assay 
Forward: 
TGTGGAGCAAGGTAGCTTAGC 
Reverse: 
TCATCGGGTGCAGAACTGAAG 
Reporter: CATGGCTGCCTCCTTG 
Rag2 Mm00501300_m1 
Runx1 - WT and Deleted Mm01213405_m1 
Runx1 - WT only Mm01213404_m1 
Runx3 Mm00490666_m1 
Selp Mm01295931_m1 
Socs1 Mm00782550_s1 
Socs2 Mm00850544_g1 
Spi1 Mm00488142_m1 
Sterile IgH 
  
  
  
Custom assay 
Forward: 
GGACTTTGGGATGGGTTTGGTT 
Reverse: 
CCCTGGTCCTAGACATCAGAGTAAT 
Reporter: CCCAGATGAAGGGCTAC 
Tcf12 Mm00441699_m1 
Tcf3 Mm01175588_m1 
Tcf7 Mm00493445_m1 
Zfp467 Mm00465678_g1 
 
